



NATIONAL HEADACHE MANAGEMENT
SYSTEM FOR ADULTS **2019**

CONTENTS

Foreword

Acknowledgements

Rationale

Methodology

SECTION 1: THE CLINICAL APPROACH

Clinical assessment of headache

The role of imaging in headache

When to consider secondary headaches

SECTION 2: PRIMARY HEADACHES

Migraine

Medication overuse headache

Tension-type headache

The trigeminal autonomic cephalalgias:

i. Cluster headache

ii. Paroxysmal hemicrania

iii. SUNCT/SUNA

iv. Hemicrania continua

List of abbreviations

References

FOREWORD

“The truth is never pure and rarely simple”

Oscar Wilde

Considerable advances have been made in the understanding of headache. To assist in management, various guidelines have been developed by different organisations in the UK and internationally. The primary purpose of guidelines, the stringency of criteria used, and the structure of the healthcare system for which they are written may differ and can result in variation. In addition, it should be acknowledged that different clinical subspecialties may also have different systematic approaches to clinical risk management.

The purpose of the BASH Headache Management System for Adults 2019 is to provide a simple, safe and standardised approach which can be used in real time to help manage the majority of common headache conditions. It has been produced with feedback from national patient charities – the Migraine Trust and the Organisation for the Study of Cluster Headache – and the Royal Pharmaceutical Society.

We hope to increase people's confidence in managing their own condition and hope the system is accessible to both patients and their clinical teams.

For people suffering from headache we are also developing downloadable information sheets for the recommended treatments, a useful and quick to complete headache diary and headache impact measurement tool, and links to useful educational videos made by members of BASH to help with greater understanding of their conditions. These resources will also be helpful to clinicians when guiding care.

The intention is that the BASH Headache Management System will encourage a national consistency in approach to caring for people with common headache disorders. The expectation is that the BASH system will largely replace the multiplicity of different regional headache algorithms and in doing so will reduce variation in care.

Through our relationship with NHS Right Care and engaging with the getting it right first-time programmes (GIRFT) we anticipate the management system will become a nationally commissioned approach to common headache conditions. Over time it will evolve to become an even more comprehensive system encompassing all headache disorders.

Fayyaz Ahmed, Hull Royal Infirmary

Anish Bahra, National Hospital for Neurology and Neurosurgery

Alok Tyagi, Queen Elizabeth University Hospital Glasgow

Stuart Weatherby, University Hospitals Plymouth

BASH Guideline Writing Committee

ACKNOWLEDGEMENTS

The guideline committee would like to express thanks to the **Migraine Trust**, the **Organisation for the Study of Cluster Headache UK**, the **Royal Pharmaceutical Society** and **BASH council** for their support, particularly in seeking patient/professional feedback on the utility of this guideline and the development of the patient information sheets.

The committee would also like to thank **Thomas Hart** (St George's Hospital, London) for his work in preparing the documents for publication.

RATIONALE

Building on the original BASH guidelines, the BASH national headache management system has been designed as a pragmatic tool to assist busy clinicians across the medical community. The purpose is to provide simple and easy to follow recommendations applicable to the majority of patients with headache.

The guidance is structured in a brief and relatively didactic fashion and reflects a deliberate decision to achieve three important aims: -

1. To create guidance useful to the clinician when seeing a patient in 'real time'
2. To assist allied health professionals in managing patients with common primary headache disorders using a relatively simple and standardised menu of care
3. To support and facilitate patients in self-management, through use of educational videos, patient information sheets and headache diaries and with a view to developing patient electronic self-management tools in collaboration with national organisations and charities

METHODOLOGY

A writing committee was established by consensus through the BASH council.

All treatments included in the guideline are supported by randomised placebo-controlled trials.

As the level of evidence supporting class A recommendations in international guidelines is not consistent, BASH has therefore chosen only to recommend treatments that are consistently considered to have class A evidence and are recommended in two or more of the following guidelines (NICE, SIGN, AHS & EFNS).

Newer treatments for headache with a specific UK license are also recommended if supported by adequately powered clinical trials with accepted IHS end points and done in a randomised placebo-controlled manner.

Other treatment options (with randomised placebo-controlled trial data) are included as appendices.

In recognition of the lack of comparative data, where relevant, treatment options are presented in alphabetical order.

The text does not include a comprehensive overview of side effect profiles, adverse events, contraindications, or drug interactions. When considering therapeutic options, standard resources should be consulted, for example the British National formulary and the product information sheets.

Both prescribers and patients should also note, that while treatment options have placebo control data, not all have a specific licence for a headache condition.

The first draft was sent to BASH council in 2018 (with 4 months for comments). The final draft was circulated in early 2019 for a further month of consultation prior to publication.

SECTION 1:

THE CLINICAL APPROACH

-  Clinical assessment of headache
-  The role of imaging in headache
-  When to consider secondary headaches

CLINICAL ASSESSMENT OF HEADACHE

Classification

Headaches are classified by the International Headache Society as primary or secondary headaches (<http://www.ichd-3.org>).

The majority of headache is primary (such as migraine). Primary headache is the best validated within this classification system (<http://www.ichd-3.org>).

Secondary headaches are precipitated by another condition or disorder, local or systemic¹⁻³. Serious causes of secondary headache are uncommon.

How to differentiate primary from secondary headache

The most consistent indicators for serious secondary headache are:

- Thunderclap (sudden onset) headache⁴⁻⁶
- Associated focal neurological deficit^{4,7,8}
- Associated systemic features^{4,7,8}
- Patients over the age over 50 years^{9,10}

The history is the key to diagnosis in headache. The neurological examination is also helpful in differentiating primary from secondary headache^{4,7,8}. For example, patients with migraine (with or without typical aura) or tension-type headache and a normal neurological examination do not have an increased likelihood of a secondary precipitant relative to the background population¹¹⁻¹³.

For other isolated headache syndromes with normal neurological examination there is insufficient data to enable a definitive conclusion¹⁴.

Using the temporal pattern of headache to help differentiate primary from secondary headache

While we acknowledge that not all the following descriptors have tight definitions, we have tried to consider different temporal clinical patterns that the 'jobbing' clinician might frequently encounter and recognise.

Sudden onset headache

Sudden onset headache reaching maximum intensity within 5 minutes is called thunderclap headache^{4-6,15-17}. Thunderclap headache has the greatest probability of a secondary precipitant⁴⁻⁶.

Recent onset and progressive headache

Evolution of headache over days to weeks. If associated systemic features and/or focal neurological signs there is an increased probability of secondary precipitant^{4,7,8}.

Recurrent episodic headache

Recurrent episodic headache in isolation is most likely due to a primary headache disorder^{13,18}.

Headache which occurs on the majority of days in a month

Headache present for at least 15 days per month for over 3 months in isolation is most likely due to a primary headache disorder¹⁸.

Differentiating between common primary headache disorders

Laterality and site of headache

Strictly unilateral (right or left but never bilateral) headache most consistently occurs in the Trigeminal Autonomic Cephalalgias (TACS) (<http://www.ichd-3.org>). 11.5- 20% of migraine sufferers experience unilateral headache^{19,20}.

Bilateral headache more commonly occurs in migraine, and is a more consistent defining feature of tension-type headache²¹⁻²³.

In most primary headache disorders the pain is experienced in the distribution of the first division of the trigeminal nerve and second cervical root. Neck pain can therefore be a feature of a migraine attack^{22,24-31}.

Associated symptoms

Prominent features in migraine include nausea, vomiting, photophobia, phonophobia and motion sensitivity (a tendency for the headache to be exacerbated by head movement or mild exertion)^{21,23,32-35}.

Cranial autonomic features, such as lacrimation, conjunctival injection, rhinorrhoea, and nasal blockage, are characteristic of the TACs, but can occur in up to 25% of migraine sufferers^{36,37}.

Unlike migraine sufferers who are frequently motion sensitive and generally prefer to remain still during an attack, patients with cluster headache and to a lesser extent TACs tend to be restless during an attack^{25-27,38}

Aura can be experienced in all headache disorders, but is by far most common in migraine³⁹.

Duration and Frequency

The majority of untreated migraine headaches last between 4-72 hours^{33,40,41}.

Untreated TACS are typically of shorter duration and with higher attack frequency⁴²⁻⁴⁹.

Table 1 shows a comparative table to distinguish between common primary headaches

Table 1. Comparative table to distinguish between common primary headaches
(based on <http://www.ichd-3.org>)

MIGRAINE	TENSION-TYPE HEADACHE	CLUSTER HEADACHE
<i>Episodic</i>		
Unilateral (although often bilateral)	Bilateral	Unilateral (never bilateral)
Pulsating	Pressing, tightening, non-pulsating	
Moderate or severe	Mild or moderate <i>but not disabling</i>	Very severe
Aggravated by, or causing avoidance of, routine physical activity	No aggravation by, or avoidance of, routine physical activity	Restlessness No aggravation by physical activity
Nausea and/or vomiting Photophobia Phonophobia	No nausea, vomiting, photophobia, or phonophobia	<i>Ipsilateral to pain, there may be:</i> Conjunctival injection Lacrimation Nasal congestion Rhinorrhoea Eyelid swelling/drooping
Attacks last hours to days (usually 4-72 hours)	Attacks last hours to days	Attacks last from 15 mins to 3 hours
Frequency 1-2 attacks per month		Frequency 1-3 attacks per day (up to 8) and usually occur daily for 2-3 months at a time
<i>Chronic</i>		
Chronic migraine or chronic tension-type headache: At least 15 headache days per month for >3 months with the above clinical description, in the absence of medication overuse		Chronic cluster headache: Attacks occurring for more than 1 year without remission, or remission periods lasting <3 months
<i>Medication-overuse headache</i>		
Ergotamine, triptans, or opioids taken on 10 or more days per month, or 15 days for simple analgesics, for >3 months. Chronic migraine is fulfilled 2 months after medication has been withdrawn without improvement		No medication overuse headache Medication-overuse headache only reported in patients with a predisposition to migraine and/or tension-type headache; clinical syndrome of the headache exacerbated by the acute-relief medication overuse is of the migraine and/or tension-type headache ⁵⁰

Examination

The presence of abnormal neurological signs significantly increases the chance of an intracranial abnormality. Therefore, an appropriate neurological examination including fundoscopy is required when assessing the patient presenting with headache.

Useful and brief ways to perform the neurological examination are found at:

<https://www.youtube.com/watch?v=wyBNYB0RLvU>

<https://www.youtube.com/watch?v=q56WgXvn0iU>

(Please see 'Useful Videos' section)

THE ROLE OF IMAGING IN HEADACHE

People suffering from headache can be anxious about the possibility of a brain tumour. Outside of an emergency setting, current data indicates that the risk of finding serious secondary pathology in patients with isolated headache and a normal neurological examination is similar to that in people who do not have headache^{8,11,12,51}.

Normal imaging can reduce subsequent health care utilisation in the short term (less than one year) presumably because of reassurance. The effect however does not appear to be sustained in patients with anxiety and depression^{8,52}.

Moreover, there is a significant potential for uncovering incidental findings in 6-15% patients, which may not necessarily require further management but can themselves increase anxiety¹⁻³, and even potentially affect insurance coverage/premiums for that individual.

An information sheet can be useful to act as an 'aide memoire' when discussing these issues ([link to information sheet about brain imaging](#)).

WHEN TO CONSIDER SECONDARY HEADACHE

Identifying headache due to secondary causes

Serious secondary headaches are uncommon^{4,7,13}. Very few secondary causes of headache have been reliably shown to have unique headache symptoms.

The most consistent indicators for secondary headache are: -

- Thunderclap (sudden onset) headache⁴⁻⁶
- Associated focal neurological deficit^{4,7,8}
- Associated systemic features^{4,7,8}
- Patients over the age over 50 years^{9,10}

There is currently poor evidence that different disease processes associated with headache have unique or specific clinical presentations not covered by the clinical indicators cited above. For example:

- Giant Cell Arteritis – onset age >50 years plus systemic features
- Idiopathic intracranial hypertension – abnormal neurological examination with papilloedema
- CNS infection – systemic features (e.g. pyrexia) +/- focal neurological features

Features that do not help to differentiate primary from secondary headaches are:

- Severity
- Clinical characteristics
- Treatment response

Neither severity⁵³ nor response to drug treatment differentiates between primary and secondary headache. For example, headaches associated with intracerebral haemorrhage⁵⁴, subarachnoid haemorrhage^{55,56}, venous sinus thrombosis⁵⁷, carotid dissection^{58,59}, and carbon monoxide poisoning⁶⁰ have all been reported to respond to simple analgesics or triptans.

There is no specific 'brain tumour' type headache. The most frequent phenotype of headache associated with brain tumours is that of episodic tension-type headache, or migraine without aura⁶¹.

Patients with the clinical syndrome of migraine (with or without typical aura) or tension type headache and a normal neurological examination do not have an increased risk of a secondary precipitant¹¹⁻¹³.

The following may be of reassurance to busy clinicians: data from the Landmark study suggest that a new clinic diagnosis of migraine was almost always correct - 98% of patients with a clinic diagnosis of migraine met international headache society criteria for migraine (87%, or probable migraine 11%)⁶².

For other isolated headache syndromes with normal neurological examination there are insufficient data to enable a definitive conclusion.

As the presence of focal or systemic symptoms and/or abnormal neurological signs significantly increases the chance of there being an abnormality, an appropriate neurological examination – including fundoscopy – is required when assessing the patient presenting with headache.

Useful and brief ways to perform the neurological examination are found at:

<http://www.youtube.com/watch?v=wyBNYB0RLvU>

<http://www.youtube.com/watch?v=q56WgXvn0iU>

(Please see 'Useful Videos' section)

Thunderclap headache

Thunderclap headache is the most common isolated headache associated with a secondary precipitant⁴⁻⁶.

The primary concern in thunderclap headache is to exclude a subarachnoid haemorrhage. In prospective studies of thunderclap headache (primary and secondary care), subarachnoid haemorrhage was present in 19.5-25%, and in 12% headache was the only symptom^{63,64}.

Investigation of Thunderclap Headache

- Refer immediately to hospital
- Urgent CT brain imaging

In patients presenting with isolated thunderclap headache with no other associated general or neurological symptoms, a normal neurological examination and a clear time of onset, the sensitivity of high resolution CT performed within 6 hours of onset is 98.5% - 99.85% for diagnosis of subarachnoid haemorrhage⁶⁵⁻⁶⁹.

This sensitivity drops to 90% after more than 6 hours⁶⁶.

Lumbar puncture

If CT brain is normal, a lumbar puncture for examination of cerebrospinal fluid should be performed.

The current consensus is based on the guidelines for the analysis of CSF for bilirubin in suspected SAH⁷⁰:

- Measure CSF pressure when performing the LP
- Send the CSF for standard constituents – protein, glucose, microbiology, and bilirubin/xanthochromia

- Send a simultaneous blood sample for glucose, bilirubin and total protein
- The specimen for spectrophotometry should be the least blood-stained fraction of CSF to be taken. The reason is that oxyhaemoglobin may interfere with the detection of bilirubin, and is a confounding element in analysis
- Protect the CSF sample for spectrophotometry from light to reduce the degradation of bilirubin, in order to minimise false-negative results
- Current consensus is that CSF should not be examined for bilirubin earlier than 12 hours after the ictus. Bilirubin in CSF forms 9-15 hours after a bleed⁷⁰⁻⁷²

If negative results are obtained from both CT brain and CSF analysis from 12 hours to within 2 weeks of the onset of thunderclap headache, it can be considered that SAH is excluded as a diagnosis^{70,73}.

Other pathologies associated with thunderclap headache

Thunderclap headache has been associated with other secondary pathologies, including infective causes, cerebrovascular causes such as intracranial haemorrhage⁷⁴, cerebral venous sinus thrombosis⁷⁵⁻⁷⁷, malignant hypertension^{78,79} and arterial dissection^{17,80-85}, non-vascular neurological causes (such as pituitary apoplexy)⁸⁶⁻⁹² and spontaneous intracranial hypertension⁹³⁻¹⁰¹. Spontaneous intracranial hypotension classically presents as an orthostatic headache^{102,103}.

If CT and CSF are normal, additional investigations may be indicated if warranted by the clinical presentation. There are a significant number of guidelines for thunderclap headache from different countries and different subspecialty organisations but there is no universal consensus as to when additional investigations are indicated. If CT or MR angiography is considered, the fact that this may identify incidental intracranial aneurysms or other abnormalities should be borne in mind¹⁰⁴.

SECTION 2: PRIMARY HEADACHES

-  Migraine
-  Medication overuse headache
-  Tension-type headache
-  The trigeminal autonomic cephalalgias:
 -  v. Cluster headache
 -  vi. Paroxysmal hemicrania
 -  vii. SUNCT/SUNA
 -  viii. Hemicrania continua

MIGRAINE

Epidemiology

Migraine is the most common disabling headache disorder, ranked as 7th highest among specific causes of disability globally and is responsible for 2.9% of all years of life lost to disability¹⁰⁵.

The global lifetime prevalence is 10% in men and 22% in women¹⁰⁶.

Peak prevalence increases to the age of 40 years and declines thereafter in both women and men, though can present de novo later in life¹⁰⁷⁻¹⁰⁹.

Chronic migraine is a highly disabling primary headache disorder that affects 2% of the population^{110,111}, with reduced quality of life¹¹², increased risk of anxiety, depression and chronic pain and greater use of healthcare resource¹¹³.

Around two-thirds of patient with chronic migraine have medication overuse¹¹⁴.

Clinical features

Migraine is characterised by recurrent episodes of moderate to severe headaches, unilateral or bilateral and frequently throbbing. There may be associated nausea/vomiting, and light, noise and/or motion sensitivity^{21,23,32-35}. (<http://www.ichd-3.org>).

Attacks can last 4-72 hours with freedom from symptoms in between, and vary in frequency from one per year to a few times per month^{33,40,41,115}.

The median frequency is one to two attacks per month¹¹⁶.

Headache on 15 or more days per month for 3 consecutive months, of which at least 8 days have features of migraine, is termed chronic migraine (<http://www.ichd-3.org>).

The most sensitive and specific features of migraine are¹¹⁷:

- Nausea
- Disability (limitation of activity)
- Photophobia

Prior to the onset of headache, patients can frequently experience premonitory symptoms, the most common of which are feeling tired (72%), difficulty concentrating (51%), and a stiff neck (50%)¹¹⁸.

After the headache has ended patients often experience postdrome symptoms of a similar nature. In most attacks (93%), there was return to normal within 24 hours¹¹⁹.

Aura affects around a third of migraine sufferers^{120,121}.

A typical aura comprises of fully reversible visual and/or sensory/ and/or speech symptoms, evolving over minutes with a total duration of up to 60 minutes (<http://www.ichd-3.org>).

Aura may occur without headache particularly in older patients¹²².

Aura usually precedes, but may occur during, or after the headache.

Aura is not unique to migraine. It may occur in other forms of primary headaches³⁹.

The current classification of migraine with or without aura is well validated^{19-21,23,33-35,40,41} (see table 2), though these classification systems are used primarily as a research tool rather than in everyday clinical practice.

Table 2: International headache classification definitions of migraine

<p>MIGRAINE WITHOUT AURA</p> <ul style="list-style-type: none"> A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) C. Headache has ≥ 2 of the following characteristics: <ul style="list-style-type: none"> a. Unilateral location b. Pulsating quality c. Moderate or severe pain intensity d. Aggravation by or causing avoidance of routine physical activity (e.g. walking climbing stairs) D. During headache ≥ 1 of the following: <ul style="list-style-type: none"> a. Nausea and/or vomiting b. Photophobia and phonophobia E. Not better accounted for by another ICHD-3 diagnosis <p>MIGRAINE WITH AURA</p> <ul style="list-style-type: none"> A. At least 2 attacks fulfilling criteria B and C B. >1 of the following fully reversible aura symptoms: 1. Visual 2. Sensory 3. Speech and/or language 4. Motor 5. Brainstem 6. Retinal C. >2 of the following 4 characteristics: <ul style="list-style-type: none"> a. 1 aura symptom spreads gradually over > 5 minutes, and/or > 2 symptoms occur in succession. b. each individual aura symptom lasts 5-60 minutes c. 1 aura symptoms are unilateral d. aura accompanied or followed in < 60 minutes by headache D. Not better accounted for by another ICHD-3 diagnosis, and TIA excluded <p>CHRONIC MIGRAINE</p> <p>Headache occurring on 15 or more days/month for more than 3 months, which, on at last 8 days/month, has the feature of migraine headache.</p> <ul style="list-style-type: none"> A. Headache (migraine-like or tension type like) on $8 \geq$ days/month for > 3 months, and fulfilling criteria B and C B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 Migraine without aura and/or criteria B and C for 1.2 Migraine with aura. C. On ≥ 8 days/month for > 3 months, fulfilling any of the following: <ul style="list-style-type: none"> a. Criteria C and D for 1.1 Migraine without aura b. Criteria B and C for 1.2 Migraine with aura c. Believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative. D. Not better accounted for by another ICHD-3 diagnosis.
--

General principles

Validate the impact the condition has on the individual and family.

Manage expectations: Patients may have low or unrealistic expectations of what is achievable. Explain that migraine cannot be cured but can be effectively managed in most cases^{123,124}.

Reassurance: Patients often worry about an underlying serious disorder. Explaining the nature of the condition to the patient can be of therapeutic value¹²⁵.

Empower the patient to help promote self-management¹²⁶.

Prescribing decisions should be made with reference to the patient's current clinical situation and their future plans (e.g. pregnancy or contraception). Potential issues of medication overuse, both with respect to the impact on headache and side effects should be discussed.

Cognitive behavioural therapy has shown a greater reduction in migraine associated disability compared to drug therapy alone¹²⁷.

Acute Treatments

When prescribing acute treatments there are two broad strategies¹²⁸:

1. **Stepped approach:** start with simple analgesics and if ineffective step-up e.g. to a triptan
2. **Stratified approach:** target treatment based on attack severity

The stratified approach is associated with better health related outcomes and lower indirect costs (e.g. GP and hospital visits)^{128,129}.

Adding an anti-emetic to an acute treatment improves efficacy unrelated to nausea and/or vomiting¹³⁰ and can improve gastric motility and hence drug absorption¹³¹⁻¹³³.

The end point of an effective treatment is a significant response at two hours, because the natural history for most attacks is to spontaneously improve in 4 hours¹³⁴.

If a treatment is not effective at 2 hours, then it is unlikely to work in that attack at that dose and considering an alternative acute treatment or combination treatment would be reasonable¹³⁵.

Lack of response to one triptan does not predict response to other triptans¹³⁵.

Triptans are most effective when taken early in the headache phase of the attack¹³⁶.

Triptans are less likely to be effective at treating the headache if taken during the preceding aura¹³⁷⁻¹³⁹.

After 2 treatment failures with a particular triptan a trial with an alternative triptan is recommended. This rationale is based on the finding that in patients who experienced treatment failure in two attacks, 70% failed to respond in the third attack. Around 30% patients do not respond to any triptan¹⁴⁰.

Acute treatments can be associated with the development of medication overuse headache¹⁴¹.

Opioids are not recommended for the treatment of acute headache because of the significant risk of medication overuse and the most protracted withdrawal¹⁴¹.

For patients attending the emergency department parenteral NSAIDs or subcutaneous sumatriptan should be considered, and evidence also supports the use

of antiemetics¹⁴². Opioids have not been shown to be significantly effective and should not be used¹⁴³.

Recommended acute treatments are included in tables 3 and 4.

Table 3. Recommended acute treatments – simple analgesics and antiemetics

DRUG	DOSE	MAXIMUM DAILY DOSE	INFORMATION
<i>Simple analgesics</i>			
ASPIRIN ¹⁴⁴⁻¹⁴⁸	600-1000 mg (UK doses are 300-900 mg)	4000 mg (for oral dosing)	
DICLOFENAC ¹⁴⁹⁻¹⁵²	25 mg	150 mg	
IBUPROFEN ¹⁵³⁻¹⁵⁵	400-600 mg	2400 mg	
KETOPROFEN ^{156,157}	75-150 mg	150 mg	
NAPROXEN ¹⁵⁸⁻¹⁶⁰	250 mg	1000 mg	
PARACETAMOL ^{133,161}	1000 mg	4000 mg	
TOLFENAMIC ACID ¹⁶²	200 mg	400 mg	
<i>Antiemetics</i>			
DOMPERIDONE ¹³³	10 mg	30 mg	Safety alert: https://www.gov.uk/drug-safety-update/domperidone-risks-of-cardiac-side-effects
PROCHLORPERAZINE ¹⁶³⁻¹⁶⁵	10 mg	30 mg	
METOCLOPRAMIDE ^{132,166,167}	10 mg	30 mg	Safety alert: https://www.gov.uk/drug-safety-update/metoclopramide-risk-of-neurological-adverse-effects

Table 4. Recommended acute treatments – triptans

DRUG	FORMULATION	STRENGTH	SINGLE DOSE	MAX/24 HOURS
ALMOTRIPTAN ^{168,169}	TABLET	12.5 mg	12.5 mg	25 mg
ELETRIPTAN ¹⁷⁰	TABLET	40 mg	40 mg	80 mg
FROVATRIPTAN ¹⁷¹	TABLET	2.5 mg	2.5 mg	5 mg
NARATRIPTAN ¹⁷²	TABLET	2.5 mg	2.5 mg	5 mg
RIZATRIPTAN ¹⁷³	TABLET	5 mg/10 mg	10 mg	20 mg
	ORODISPERS	10 mg	10 mg	20 mg
	LYPOPHILLISATE	10 mg	10 mg	20 mg
SUMATRIPTAN ^{137,174}	TABLET	50 mg/100 mg	50-100 mg	300 mg
	SPRAY	100 mg/ml or 200 mg/ml	10 - 20 mg	
	SUBCUT INJ	6 mg	6 mg	12 mg
ZOLMITRIPTAN ¹⁷⁵⁻¹⁷⁷	TABLET	2.5 mg/5 mg	5 mg	10 mg
	ORODISPERS	2.5 mg/ 5 mg	5 mg	10 mg
	SPRAY	50 mg/ml	5 mg	10 mg

Choosing a triptan

Sumatriptan 6 mg subcutaneous remains the most rapid and effective treatment for pain relief but has a higher risk of adverse events than other formulations.

Combination of a triptan and an NSAID with a long half-life, such as naproxen, is better than monotherapy¹⁷⁸.

In comparison to sumatriptan 100 mg^{171,179-181}:

- **Lower adverse events:** naratriptan 2.5 mg, almotriptan 12.5 mg and frovatriptan 2.5 mg
- **Better 2-hour pain response:** eletriptan 80 mg and rizatriptan 10 mg, almotriptan 12.5 mg
- **Lower recurrence rate:** frovatriptan 2.5 mg, and eletriptan 40 mg

Contraindications to triptans include ischaemic heart disease, cerebrovascular disease, previous myocardial infarction, and uncontrolled or severe hypertension. The cardiovascular risk of triptans is very low in the absence of these contra-indications¹⁸².

The NNTs for therapies to achieve the outcome of pain freedom at two hours from a baseline of moderate to severe pain can be accessed by the SIGN guideline (www.sign.ac.uk/assets/sign155.pdf).

Preventive Treatments

General Principles

Prescribing decisions should be made with reference to the patient's current clinical situation and their future plans (e.g. pregnancy or contraception).

Preventive treatment should be offered as an option to patients with 4 or more migraine days a month as this frequency is associated with significant disability. Such

an approach will also mitigate the risk of escalation of acute treatment and consequent development of medication overuse headache.

Acute treatment on more than 2 days per week is associated with medication overuse, which renders preventive treatment less effective¹⁸³.

As there are relatively few head to head comparative studies, the choice of preventive depends primarily upon the side-effect profile of the drug and co-existing morbidities.

Preventive medications must be titrated slowly to an effective or maximum tolerable dose and continued for at least 6-8 weeks to adequately assess effect^{184,185}.

A headache diary may help evaluate response to treatment.

Consider gradual withdrawal after 6-12 months of effective preventive¹⁸⁴.

Monitor quality of life through validated tools such as HIT-6¹⁸⁶. The HIT-6 score can be downloaded at <http://www.bash.org.uk/wp-content/uploads/2012/07/English.pdf>, or can be found in the information sheet section of these guidelines (Patient reported outcome measure HIT-6).

Treatment options

In selecting a preventative treatment, a reasonable strategy would be to consider which options might be most suitable for the individual patient, given their previous treatment, medical and other co-morbidities, personal preferences, and side effect profiles of the various treatments.

Table 5 shows the dose and titration regimen for recommended preventive treatments in both episodic and chronic migraine.

Table 6 shows dose and treatment regimen for recommended preventive treatments in chronic migraine only.

All preventive treatments with randomised placebo-controlled trial data are listed as an appendix.

Table 5. Recommended preventive treatments in episodic and chronic migraine

DRUG	START DOSE	TITRATION	TRIAL STUDIED DAILY DOSES
Amitriptyline ¹⁸⁷⁻¹⁹¹	10-25 mg OD	10 -25 mg	25-150 mg
Candesartan ^{192,193}	2 mg OD	2 mg	8-16 mg total/day
Propranolol ^{187,194,195}	10 mg BD	10-20 mg BD	120-240 mg total/day
Topiramate ¹⁹⁶⁻²⁰⁵	25 mg daily	25 mg od	25-200 mg total/day
<i>CGRP monoclonal antibodies</i>			
Erenumab ²⁰⁶⁻²⁰⁹	70-140 mg monthly	Max dose as per licensed indication	
Fremanezumab ²¹⁰	225 mg monthly 675 mg three-monthly	Max dose as per licensed indication	
Galcanezumab ²¹¹⁻²¹³	120-240 mg monthly	Max dose as per licensed indication	

Table 6. Recommended preventive treatments for chronic migraine only

Onabotulinumtoxin A ²¹⁴⁻²¹⁸	155-195 IU intramuscularly, as per PREEMPT protocol	Every 12 weeks
--	---	----------------

Onabotulinumtoxin A

The efficacy and safety of Onabotulinumtoxin A for prophylaxis of Chronic Migraine has been shown through in the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical programme.

Patient selection: Treatment is licensed for adult patients with chronic migraine. Treatment is not effective in episodic migraine (< 15 days a month).

BASH considers it good practice to address medication overuse prior to commencing Botox treatment. Patients are advised to restrict their acute headache medication to no more than two days a week on a regular basis.

As 60% of patients failed two oral preventive treatments in the PREEMPT trial, BASH recommends considering use of 2-3 oral preventive treatments prior to Botox therapy.

Treatment response should be monitored using quality of life measures, for example HIT-6.

Appendix 1. All preventive treatments for migraine

DRUG	START DOSE	INCREMENT	MAX DOSE	COMMENTS
Acupuncture ²¹⁹	10 sessions			
<i>Angiotensin Receptor Blockers/ACE inhibitors</i>				
Candesartan ^{192,193}	2 mg/day	2 mg	8 mg BD	
Lisinopril ²²⁰	10 mg/day	10 mg	20 mg/day	
<i>Anticonvulsants</i>				
Topiramate ¹⁹⁶⁻²⁰⁵	25 mg/day	25 mg	100 mg BD	
Sodium Valproate ²²¹⁻²²⁷	200 mg BD	100 mg	1000 mg BD	MHRA and NHS safety alerts*
<i>Beta Blockers</i>				
Propranolol ^{187,194,195}	10-20 mg BD	10-20 mg	120-240 mg/day	
Metoprolol ²²⁸⁻²³⁰	25-50 mg/day	50mg BD	200 mg total daily in BD or TDS regimen	
Nadolol ²³¹	40 mg/day	40 mg	160 mg/day	
Timolol ²³²	10 mg BD	10 mg	30 mg BD	
Atenolol ²³³	50 mg/day	50 mg	200 mg/day	
<i>Calcium Channel Blockers</i>				
Flunarizine ²³⁴⁻²³⁶	5 mg/day	5 mg	10 mg/day	Not marketed in the UK
<i>CGRP monoclonal antibodies</i>				
Erenumab ²⁰⁶⁻²⁰⁹	70-140 mg monthly		Max dose as per licensed indication	
Fremanezumab ²¹⁰	225 mg monthly 675 mg three-monthly		Max dose as per licensed indication	
Galcanezumab ²¹¹⁻²¹³	120-240 mg monthly		Max dose as per licensed indication	
Greater Occipital Nerve Block ²³⁷⁻²⁴⁰	Local anaesthetic +/- steroids SC		Not applicable if using local anaesthetic only	4 small RCT - 3 showing reduced headaches frequency over 1-4 weeks
Onabotulinumtoxin A ²¹⁴⁻²¹⁸	155 IU		195 IU	IM every 3 months
<i>Neuromodulation</i>				
External Trigeminal Nerve Stimulation ²⁴¹	As per specialist recommendations			
Single Transcranial Magnetic Stimulation ²⁴²	As per specialist recommendations			During aura or start of headache
Transcutaneous Vagal Nerve Stimulation ²⁴³	As per specialist recommendations			

Supplements				
Co-enzyme Q10 ²⁴⁴	150 mg/day			
Magnesium ²⁴⁵	400 mg/day	200 mg	600 mg/day	
Riboflavin ²⁴⁶	400 mg/day			
Tricyclic Antidepressants				
Amitriptyline ¹⁸⁷⁻¹⁹¹	10 - 25 mg/day	10 - 25 mg	150 mg ON	

***Valproate Patient Safety Alert**

In girls and women of childbearing potential, valproate should be initiated and supervised by a specialist and only prescribed when other medications have not been tolerated or have found to be ineffective. This is because of 30-40% risk of neurodevelopmental disability in unborn babies exposed to valproate (MHRA April 2017). Valproate should only be prescribed by following the MHRA guidance, including a signed contraceptive plan and signed consent form documenting discussion of the risks (see MHRA website)

<https://www.gov.uk/drug-safety-update/valproate-and-developmental-disorders-new-alert-asking-for-patient-review-and-further-consideration-of-risk-minimisation-measures>

https://improvement.nhs.uk/documents/911/Patient_Safety_Alert_-_Resources_to_support_safe_use_of_valproate.pdf

Menstrual Migraine

A proportion of women suffer from migraine attacks in association with the menstrual cycle, termed menstrual related migraine (MRM). MRM occurs between days -2 and +3 of the first day of menstruation (which is +1) in at least 2 out of 3 menstrual cycles.

Women with MRM will also have attacks at other times.

Less than 10% of women report migraine exclusively with menstruation and at no other time ('pure' menstrual migraine)²⁴⁷⁻²⁵³

Acute Treatment

The acute treatment of menstrual related attacks is no different to non-menstrual attacks.

Head-to-head studies do not show clear superiority of one triptan over any other²⁵⁴.

Recommended short term preventive treatments for menstrual related migraine, or pure menstrual migraine.

Table 7. Recommended triptans for short term prevention of menstrual related migraine or pure menstrual migraine

DRUG	FORMULATION	STRENGTH
FROVATRIPTAN ^{255,256}	TABLET	2.5 mg twice daily on the days migraine is expected (generally from two days before until three days after bleeding starts).
ZOLMITRIPTAN ²⁵⁷	TABLET	2.5 mg twice or three times a day on the days migraine is expected (generally from two days before until three days after bleeding starts).

Appendix 2. All treatments for short term prevention of menstrual related migraine or pure menstrual migraine

DRUG	FORMULATION	STRENGTH
FROVATRIPTAN ^{255,256}	TABLET	2.5 mg twice daily on the days migraine is expected (generally from two days before until three days after bleeding starts)
NARATRIPTAN ^{258,259}	TABLET	2.5 mg twice daily on the days migraine is expected (generally from two days before until three days after bleeding starts)
ZOLMITRIPTAN ²⁵⁷	TABLET	2.5 mg twice or three times a day on the days migraine is expected (generally from two days before until three days after bleeding starts)

Targeted oestrogen supplementation

Menstrually targeted oestrogen supplementation (assuming no contraindications) has been found in some studies to offer benefit in menstrual related migraine²⁶⁰⁻²⁶².

However, a rebound increase in migraine attack frequency has been found when the effect of this strategy has been considered over the whole menstrual cycle²⁶³.

The risk of stroke in migraine with aura, when taking oestrogen-containing contraceptives

Females suffering migraine with aura have an inherent increased risk of stroke²⁶⁴.

Use of the oestrogen contraceptive pill is also associated with increased risk of stroke in all individuals. The incidence of stroke in females with migraine with aura, who are also taking the oestrogen-containing contraceptive pill is additionally increased.

Consequently, contraceptive methods other than oestrogen containing contraception are advised for women with migraine with aura. There is no established additional risk in migraine without aura.

Treatment in pregnancy & breast feeding

- In the majority of women, migraines improve during pregnancy^{265,266}
- Caution is advised and checking with British National formulary data and pregnancy register is recommended especially when prescribing in pregnancy, breast feeding, and considering contraception. The resource Best Use of Medicine in Pregnancy (BUMPS) may also be of help to patients (<http://www.medicinesinpregnancy.org/>)
- Paracetamol is not generally considered to be associated with a significantly elevated risk throughout pregnancy and lactation²⁶⁷
- The Sumatriptan & Naratriptan Pregnancy Registry found no evidence of teratogenicity associated with major birth defects for sumatriptan²⁶⁸⁻²⁷¹

MEDICATION OVERUSE HEADACHE

Epidemiology & diagnosis

In patients with migraine or tension-type headache, regular frequent use of acute treatment can result in exacerbation of the pre-existing primary headache²⁷².

Medication overuse headache (MOH) is classified as a chronic headache disorder. The headache occurs on more than 15 days a month for at least 3 months, affecting between 1-2% of the general population and, up to 20-50% of the chronic headache population^{105,106,273-276}.

MOH has been recognized since the 1940s and is a worldwide issue resulting from an interaction between frequently used acute headache medication in a susceptible patient^{277,278}.

Majority of patients improve on withdrawal of the overused medication²⁷⁹⁻²⁸³.

All medications used to treat an acute headache can result in medication overuse headaches. Triptans, opioids and combination analgesics are likely to result in development of MOH more rapidly (treatment taken on 10 days or more per month) as compared to simple analgesics such as paracetamol (treatment taken on 15 days or more per month)^{141,272,284-286}.

MOH occurs primarily in individuals with migraine or tension type headache and is generally of the same phenotype¹⁴¹.

Overuse of triptans has been shown to cause MOH faster and with fewer doses compared with analgesics. The average interval between the first intake and daily MOH was 1.7 years for triptans, 2.7 years for ergots and 4.8 years for analgesics¹⁴¹.

Patients must provide details of their usage of both prescription medications and of treatments taken over the counter.

Clinicians must specifically ask how many days in a month the patient takes medication for treating the acute headache and preferably correlate this with a headache diary.

In patients with a history of migraine or tension type headaches pain killer medication taken regularly for non-headache pain, such as joint or back pain, can result in medication overuse headaches^{278,287}.

The association between analgesic overuse and chronic pain is strongest for chronic migraine (odds ratio of 10.3)²⁸⁸.

Clinical features

Triptan overuse may result in daily migraine like headache or an increase in migraine frequency, whereas overuse of other analgesics may lead to daily headache with features of both migraine and tension type headache¹⁴¹.

Many patients continue to take their acute medications despite the apparent lack of effect, while also reporting significant rebound in headache when acute medications are not taken²⁷⁹⁻²⁸³.

The prevalence of comorbid psychiatric disorders, including depression and anxiety, is greatly increased in patients with MOH. In patients with medication overuse headache with pre-existing episodic tension type headache 67.7% have comorbid psychiatric disorders while in those with pre-existing migraine these were present in 53.7%. Depression and anxiety themselves also be risk factor²⁸⁹.

Migraine is comorbid with depression and anxiety and these may be risk factors for developing MOH^{290,291}.

Dependence related behaviour is noted in 60–70% patients and relapses are common²⁹⁰.

Management

Patient education

An important aspect in the management of MOH is to increase awareness of the condition amongst health care providers as well as the general population.

Patients must be advised that restricting their acute headache medications to no more than 2 days in a week minimizes the potential of developing MOH²⁹².

Educational intervention is crucial and results in improvement in headache²⁹³.

Comparison of advice alone with a structured detoxification program in patients with MOH is similarly effective²⁹⁴.

The use of rescue medications, including steroids, does not improve outcomes²⁹⁴⁻²⁹⁷.

Patients should be encouraged to seek preventive treatments for migraine as this can prevent the conversion from episodic to chronic migraine thereby reducing the risk of development of MOH²⁹⁸.

Medication withdrawal

The MOH is unlikely to resolve unless the offending medication is stopped²⁹⁹.

There is no difference in outcome with either abrupt or gradual withdrawal of the causative drug³⁰⁰.

Outpatient medication withdrawal is as effective as inpatient detoxification^{294,301,302}.

Withdrawal headache usually lasts for 2-10 days from the time of complete cessation of the overused medication^{114,303,304}.

After medication withdrawal patient's headaches gradually improve. This improvement can take up to 12 weeks²⁸⁶.

The average duration of withdrawal headache appears to be shortest in patients overusing triptans (4 days)³⁰⁵.

Response to acute and preventive medications improves following withdrawal of the overused medication^{299,306}.

Prognosis

At 8 weeks following medication withdrawal 45% of patients report improvement in headaches while in 48 % the headaches remain unchanged²⁹⁹ (though it must be noted that this data is from a single trial).

Between 22 – 45% patients relapse back into MOH within 1 year, and 40 – 60% within 4 years of withdrawing from their overused medications^{307,308}.

The relapse rate is lower for patients with migraine and for individuals overusing triptans rather than analgesics (21% vs 71%)³⁰⁸.

Comorbid anxiety and depression can be associated with difficulty in medication withdrawal and a high risk of relapse following withdrawal of medication²⁹⁰.

Response to migraine preventive medications improves following withdrawal of the overused acute headache medication^{299,309}.

There is no difference in outcome if preventive medication is started during or after withdrawal, as long as the acute medication is withdrawn. Preventive treatment is more effective once the overused medication is withdrawn^{183,201,306,310}.

The most important step in MOH management is to identify the diagnosis and inform the patient of the importance of reducing or stopping the offending medication, and no further measures may then be required³¹¹⁻³¹³.

TENSION-TYPE HEADACHE

Epidemiology

Tension-Type Headache (TTH) is the most common primary headache disorder with a mean global lifetime prevalence of 42% (Range 19-83%)³¹⁴. Chronic tension-type headache affects 0.5 - 4.8 % of the worldwide population³¹⁵.

Clinical features

TTH is characterised by mild-moderate and *not severe*, headache. It is bilateral and often described as pressing or tightening like a vice or tight band.

It **typically** lacks the specific features that characterise migraine such as nausea, light and noise sensitivity.

The headache is *not* aggravated by routine physical activity and this is a key criterion for diagnosis^{21,316-318}.

Duration of pain can be variable with a range from half an hour to several days. TTH on 15 or more days per month for at least 3 months is termed chronic TTH.

Disabling TTH is rare. Most patients diagnosed with disabling TTH have migraine, and respond to triptans^{319,320}.

Management

Reassurance may suffice in the majority of patients.

Individual attacks can be treated with simple analgesics (see table 8).

Table 8. Recommended acute treatments in tension-type headache

ANALGESIC	SINGLE DOSE	MAXIMUM DAILY DOSE
Paracetamol ³²¹⁻³²³	1000 mg	4000 mg
Aspirin ^{324,325}	500-1000 mg (UK doses are 300-900 mg)	4000 mg (for oral dosing)

Preventive treatment is rarely necessary, though can be considered if symptoms are causing significant disability (see table 9).

Table 9. Recommended preventive treatment in tension-type headache

DRUG	STARTING DOSE	TITRATION	MAXIMUM DOSE
Amitriptyline ³²⁶⁻³³⁰	10 mg	10-25 mg	150 mg

Appendix 3. All acute treatments in tension-type headache

TREATMENT	SINGLE DOSE	MAX DAILY DOSE
Aspirin ^{324,325,331}	500-1000 mg (UK doses are 300-900 mg)	4000 mg (for oral dosing)
Diclofenac ³³²	25-75 mg	150 mg
Ibuprofen ^{331,333,334}	400 mg	2400 mg
Ketoprofen ³³⁴⁻³³⁸	50 mg	300 mg
Naproxen ³³⁹	250-500 mg	1000 mg
Paracetamol ³²¹⁻³²³	1000 mg	4000 mg

Appendix 4. All preventive treatments in tension-type headache

TREATMENT	STARTING DOSE	TITRATION	MAXIMUM DAILY DOSE
Acupuncture ³⁴⁰⁻³⁴⁷	6 treatment sessions		
Amitriptyline ³²⁶⁻³²⁹	10 mg	10-25 mg	150 mg

THE TRIGEMINAL AUTONOMIC CEPHALAGIAS

The trigeminal autonomic cephalalgias are a group of headache disorders with prominent autonomic features and a shared pathophysiology^{348,349}.

There are four trigeminal autonomic cephalalgias. Each disorder can be either episodic or chronic.

The trigeminal autonomic cephalalgias are uncommon headache disorders. Therefore, there is a high misdiagnosis rate^{350,351} and few randomised-controlled treatment trials.

The clinical characteristics of the trigeminal autonomic cephalalgias as defined by the International Classification of Headache Disorders are based upon the published cases reports and series apart from cluster headache which has population-based data.

The trigeminal autonomic cephalalgias are:

- i. **Cluster headache**
- ii. **Paroxysmal hemicrania**
- iii. **SUNCT/SUNA** (Short-lasting neuralgiform attacks with conjunctival injection and tearing/Short-lasting neuralgiform attacks with cranial autonomic features)
- iv. **Hemicrania continua**

CLUSTER HEADACHE

Epidemiology

- Cluster headache has a prevalence of about 0.1%³⁵²
- The peak age of onset is between the 3rd and 4th decades^{25,42,353-356}
- The disorder is four times more common in men³⁵²
- Cluster headache sufferers are often smokers^{25,43,348}

Clinical features

The current classification of cluster headache is well validated (<http://www.ichd-3.org>).

Attacks are characterised by excruciating strictly unilateral and strictly unilateral headache. However, attacks can change side, across different bouts, within the same bout and rarely within an acute attack^{26,27,37,38,42,353,355,357}.

Bilateral pain in cluster headache is rare^{25,42,358-360}.

The attacks are accompanied by ipsilateral cranial autonomic features which are primarily parasympathetic and can most commonly include lacrimation, conjunctival injection, rhinorrhoea, nasal congestion, drooping or swelling of the eyelid. The presence of cranial autonomic features in headache does not necessarily indicate cluster headache or another TAC. For example, these features can also occur in migraine.

One of the most distinguishing features during the cluster attack is restlessness. Patients typically walk up and down, or rock to and fro, clutching the affected side, unlike migraineurs who are motion-sensitive and prefer to remain still^{25-27,38}.

Attack duration is usually between 15 minutes to 3 hours and attack frequency 1-2 a day. Cluster headache can be episodic or chronic. Episodic cluster bouts usually last between 2 weeks and 3 months and most often occur once every 1-2 years. Ten to 20% of sufferers experience chronic cluster headache, which is currently defined as attacks occurring without a remission period, or with remissions lasting < 3 month, for at least 1 year^{38,42,44,353-355,357}.

Active bouts of cluster headache can be seasonal and at the same time each year. During an active bout, sufferers can experience attacks at set times during the day for weeks or months. The pattern can change or become less predictable^{25,45,353,355,361,362}.

Cluster attacks often wake patients *from* sleep, usually about 1.5-2 hours after they have fallen asleep^{25,27,37,363,364}.

Some individuals can exclusively have nocturnal attacks³⁷.

In between attacks of pain patients can experience a background dull ache in the same distribution of the cluster attacks. The interparoxysmal pain tends to settle when the cluster bout resolves³⁶⁵.

During an active cluster bout some patients can be exquisitely sensitive to alcohol triggering an attack, usually within an hour. The propensity does not occur out of the bout³⁶⁶.

Clinically relevant commonalities and differences between migraine and cluster headache include:

- Cluster sufferers can have nausea and vomiting, photophobia and phonophobia^{25-27,38}

- Up to 25% of migraine sufferers can experience autonomic features during an attack³⁷
- Aura can be experienced in up to 23% of cluster headache sufferers^{27,38,360,367} (though in practice is rare)
- 20-40% of migraine sufferers experience strictly unilateral headache^{19,24}
- The duration of untreated migraine attacks in adults is invariably longer than 4 hours^{35,41}
- A key feature in cluster headache is restlessness and lack of motion sensitivity, while migraine sufferers prefer to be still^{25-27,38}

Management

Acute Treatment

The most effective acute treatment is the sumatriptan 6mg subcutaneous injection with significant relief within 15 minutes³⁶⁸.

The maximum limit is two 6mg injections a day³⁶⁹.

The treatment is generally well tolerated, without tachyphylaxis^{370,371}.

Patients who have cluster headache rarely develop medication overuse headache^{370,371}.

Patients who also have migraine may develop exacerbation of their migraine disorder whilst using a triptan effectively for their cluster attacks^{50,372}.

High flow oxygen 100% at 7-15 litres/minute for 15-20 minutes, using a non-rebreathable mask, is effective in aborting acute attacks of cluster headache^{373,374}.

There is no limit to the use of high flow oxygen, though obvious cautions around smoking/flames/fire hazards near oxygen need to be considered/addressed. Oxygen is often used together with triptans in patients with multiple attacks. Table 10 shows recommended acute cluster attack treatments.

Table 10. Recommended Acute Cluster attack treatments

Treatment	Formulation	Strength	Maximum Daily Dose
Oxygen ^{373,374}	Inhalation through non-rebreathable mask	7-15 L/min	No limit
Sumatriptan ³⁶⁸	Subcutaneous injection	6 mg	12 mg
Sumatriptan ³⁷⁵	Nasal spray	20 mg	40 mg
Zolmitriptan ³⁷⁶⁻³⁷⁸	Nasal spray	5 mg	15 mg
Non-invasive vagal nerve stimulation ³⁷⁹	Transcutaneous	As per specialist recommendation	

Appendix 5: All acute cluster attack treatments

Name	Formulation	Strength	Maximum Daily Dose	Comment
Lidocaine ³⁸⁰	Nasal spray	4%	Not specified	Self – administered using a nasal dropper
Octreotide ³⁸¹	Subcutaneous injection	100 mcg	Not specified	
Oxygen ^{373,374}	Inhalation through non-rebreathable mask	7-15 L/min	No limit	
Sphenopalatine Ganglion Stimulation (SPG) ^{382,383}	Implantable device	As per specialist recommendation		
Sumatriptan ³⁶⁸	Subcutaneous injection	6 mg	12 mg	
Sumatriptan ³⁷⁵	Nasal spray	20 mg	40 mg	
Zolmitriptan ³⁷⁶⁻³⁷⁸	Nasal spray	5 mg	15 mg	

Preventive treatments

Verapamil is an effective preventive treatment in cluster headache³⁸⁴.

The doses required to suppress cluster headache attacks can be higher than those used to treat cardiac disorders. Clinically significant cardiac rhythm disturbances can occur and are neither dose nor time dependent^{385,386}. It is possible for patients to develop cardiac conduction abnormalities even after they have been on a stable dose for a long period.

BASH recommends an ECG done at baseline and following each increase in dose. At a stable dose ECG should be done once every six months. Any cardiac rhythm disturbance may require dose reduction or drug withdrawal³⁸⁵.

In episodic cluster headache, once control has been achieved, towards the end of the expected bout, the preventive can be slowly withdrawn. If attacks recur the preventive should be re-established.

Oral corticosteroids have been shown to be effective in the prevention of cluster headache attacks³⁸⁷.

The response should be seen within 48 hours. Given the high adverse effect profile corticosteroid use is best restricted as a short-term measure in patients with multiple daily attacks, which cannot be treated effectively acutely, whilst an alternative preventive is being introduced.

Suboccipital nerve block (i.e. suboccipital depot steroid and local anaesthetic injection) has shown a significant reduction or resolution of attacks compared to placebo and despite a high placebo response rate^{388,389}.

Table 11 shows recommended preventive treatments for cluster headache.

Table 11: Recommended preventive treatments for cluster headaches

Name	Start dose	Titration	Max daily dose	Comments
Greater occipital nerve block ^{388,389}	Depot steroid + local anaesthetic	Not applicable	Not applicable	Different formulations of steroid & anaesthetic used*
Verapamil ³⁸⁴	80 mg TDS	Increase 80 mg every 2 weeks	960 mg	ECG monitoring recommended

*There does not seem to be a difference between different local anaesthetics

Appendix 6: All preventive treatments for cluster headaches

Name	Start dose	Increment	Max daily dose	Comments
Greater occipital nerve block ^{388,389}	Depot steroid + local anaesthetic	Not applicable	Not applicable	Different formulations of steroid & anaesthetic used*
Lithium ³⁹⁰	200 mg/day	200 mg/week	According to serum lithium levels. Note preparations vary widely in bioavailability	Monitor levels as per BNF
Melatonin ³⁹¹	10 mg		10 mg	
Non-Invasive Vagal Nerve Stimulation ³⁷⁹	As per specialist recommendation			
Prednisolone/pr ednisone ^{387,392}	40mg for 10-14 days	Taper thereafter	Short term interim use only	
Sphenopalatine Ganglion Stimulation ^{383,393}	As per specialist recommendation			
Verapamil ³⁸⁴	80 mg TDS	Increase 80 mg every 2 weeks	960 mg	ECG monitoring recommended

*There does not seem to be a difference between different local anaesthetics

Appendix 7: Classification of cluster headache (<http://www.ichd-3.org>)

CLUSTER HEADACHE DIAGNOSTIC CRITERIA

- A. Severe/very severe unilateral orbital, supraorbital and/or temporal pain lasting 15–180 minutes (untreated)
- B. Either or both of the following:
 - 1. At least one of the following symptoms or signs, ipsilateral to the headache:
 - a. Conjunctival injection and/or lacrimation
 - b. Nasal congestion and/or rhinorrhoea
 - c. Eyelid oedema
 - d. Forehead and facial sweating
 - e. Forehead and facial flushing
 - f. Sensation of fullness in the ear
 - g. Miosis and/or ptosis
 - 2. A sense of restlessness or agitation
- C. Attack frequency between one every other day up to 8/day for > half the time the disorder is active

EPISODIC CLUSTER HEADACHE

- A. Attacks fulfilling criteria for Cluster headache and occurring in bouts (cluster periods)
- B. At least two cluster periods lasting from 7 days to one year (when untreated) and separated by pain-free remission periods of three months

CHRONIC CLUSTER HEADACHE

Attacks fulfilling criteria for Cluster headache and occurring without a remission period, or with remissions lasting < 3 months, for at least 1 year

PAROXYSMAL HEMICRANIA

Epidemiology

Population-based data on the prevalence of paroxysmal hemicrania is sparse and has been cited as 0.05% in the 18-65-year age group³⁹⁴.

Total published cases remain less than 200.

There may be a slight female preponderance with ratios ranging between 1.1 to 2.36.

Mean age of onset is between the 4th and 5th decades^{46,395,396}.

Clinical features

The pain is strictly unilateral with associated ipsilateral autonomic features (<http://www.ichd-3.org>).

The classification of paroxysmal hemicranias is shown as an appendix.

Attack duration ranges between 2-30 minutes and frequency of attacks is reported up to 50 a day. The mean lies between seven and 13 attacks per day^{46,395}.

A greater proportion present with chronic paroxysmal hemicrania. The disorder has an absolute response to indomethacin^{46,47,395-397}.

The attacks are shorter and more frequent than in cluster headaches and longer and less frequent than in SUNCT/SUNA. The typical circadian characteristics seen in cluster headache are less prominent in paroxysmal hemicrania. All attacks are spontaneous unlike SUNCT/SUNA, in which attacks are often triggered immediately by various sensory stimuli. The key distinction is the clear therapeutic response to Indomethacin. The main differential diagnoses are shown as an appendix.

Management

There are no RCTs for preventive treatment in paroxysmal hemicranias.

Acute treatment

The attacks of paroxysmal hemicrania are usually too short to respond to any oral acute treatment. Open label observation suggests that sumatriptan 6mg subcutaneous injection and high flow oxygen are generally not effective^{398,399}.

Preventive treatment

By definition paroxysmal hemicrania is an indomethacin-responsive disorder.

The effective dose range is between 25-300mg daily dose^{46,397}.

Although most patients show a rapid response to indomethacin, some patients can take up to a week to demonstrate a response to an effective dose. Based upon this BASH recommends indomethacin 25mg PO TDS for 7 days, 50mg TDS 7 days, up to 75mg TDS. We recognise and emphasise the higher dose is above the BNF quoted maximum of 200mg per day, and should only be considered if clinically required, after appropriate counselling with the patient, and with clear criteria for dose reduction.

Dose requirements can change over time and some patients may go into remission⁴⁰⁰.

Therefore, once symptoms are well controlled for a period of time gradual dose reduction should be tried to maintain the lowest effective dose or, if there is no recurrence on each dose reduction, withdrawal during remission periods.

Gastrointestinal side effects with indomethacin are common and may preclude use of the drug. A concomitant proton-pump blocker or H₂-antagonist can be used.

SHORT-LASTING UNILATERAL NEURALGIFORM HEADACHE ATTACKS WITH CRANIAL AUTONOMIC FEATURES (SUNA)

The original description of this disorder was termed SUNCT, short-lasting unilateral neuralgiform attacks with conjunctival injection and tearing⁴⁸.

Conjunctival injection and tearing (lacrimation) are the most common autonomic symptoms in all the TACs^{26,27,30,38,42,395,396}.

The terminology SUNA was proposed based on the fact that a number of patients were noted to lack one or both of these symptoms^{49,401}. The distinction remains within the ICHD classification. From a clinical perspective, management remains the same.

The distinction remains within the ICHD classification. BASH recommends this as a research tool and for current clinical purposes will adopt the terminology of SUNA to encompass both groups⁴⁹.

Epidemiology

SUNCT/SUNA is rare^{401,402}.

The mean age of onset is 48 years with a slight male preponderance 1.5⁴⁰³.

Clinical features

The attacks are the shortest and most frequent of all the TACs. Attacks can be either spontaneous or induced by cutaneous triggers. Mean duration is about one minute (range 1-600 seconds) with frequency up to 30 attacks in an hour³¹.

The character of the attacks can vary: attacks can occur in single stabs, a group of stabs or a long attack with a 'saw-tooth' pattern of stabs between which the pain does not return to baseline. Other features of TACs may be present, such as agitation. SUNCT/SUNA can be misdiagnosed as Trigeminal Neuralgia. However, the location of the pain, autonomic features, duration of attacks and spontaneity of attacks in SUNCT/SUNA, differentiate between the two (See appendix Table. Differential diagnosis of The Trigeminal Autonomic Cephalalgias).

Management

There are no RCTs for preventive treatment in SUNCT/SUNA.

Acute treatment

Because of the short attack duration there are no effective acute treatments in SUNCT/SUNA⁴⁹.

Preventive treatment

The most effective reported treatment is lamotrigine with dose range up to 400 mg. Topiramate may be effective in SUNCT³⁸⁵. Carbamazepine and gabapentin may also be effective^{31,49,404}.

Appendix 8. Classification of paroxysmal hemicranias (<http://www.ichd-3.org>)

PAROXYSMAL HEMICRANIA

- A. At least 20 attacks fulfilling criteria B-E
- B. Severe unilateral orbital, supraorbital and/or temporal pain lasting 2-30 minutes
- C. Either or both of the following:
 - 1. At least one of the following symptoms or signs, ipsilateral to the headache:
 - a. conjunctival injection and/or lacrimation
 - b. nasal congestion and/or rhinorrhoea
 - c. eyelid oedema
 - d. forehead and facial sweating
 - e. miosis and/or ptosis
 - 2. A sense of restlessness or agitation
- D. Occurring with a frequency of >5 per day
- E. Prevented absolutely by therapeutic doses of indomethacin
- F. Not better accounted for by another ICHD-3 diagnosis.

EPISODIC PAROXYSMAL HEMICRANIA

- A. Attacks fulfilling criteria for 3.2 *Paroxysmal hemicrania* and occurring in bouts
- B. At least two bouts lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of ≥3 months.

CHRONIC PAROXYSMAL HEMICRANIA

- A. Attacks fulfilling criteria for 3.2 *Paroxysmal hemicrania*, and criterion B below
- B. Occurring without a remission period, or with remissions lasting <3 months, for at least 1 year

HEMICRANIA CONTINUA

- A. Unilateral headache fulfilling criteria B-D
- B. Present for >3 months, with exacerbations of moderate or greater intensity
- C. Either or both of the following:
 - 1. at least one of the following symptoms or signs, ipsilateral to the headache:
 - a. conjunctival injection and/or lacrimation
 - b. nasal congestion and/or rhinorrhoea
 - c. eyelid oedema
 - d. forehead and facial sweating
 - e. miosis and/or ptosis
 - 2. a sense of restlessness or agitation, or aggravation of the pain by movement
- D. Responds absolutely to therapeutic doses of indomethacin
- E. Not better accounted for by another ICHD-3 diagnosis.

REMITTING HEMICRANIA CONTINUA

- A. Headache fulfilling criteria for 3.4 *Hemicrania continua*, and criterion B below
- B. Headache is not daily or continuous but interrupted (without treatment) by remission periods of ≥ 24 hours.

UNREMITTING HEMICRANIA CONTINUA

- A. Headache fulfilling criteria for 3.4 *Hemicrania continua*, and criterion B below
- B. Headache is daily and continuous for at least 1 year, without remission periods of ≥ 24 hours.

SHORT-LASTING UNILATERAL NEURALGIFORM HEADACHE ATTACKS (SUNCT)

- A. At least 20 attacks fulfilling criteria B–D
- B. Moderate or severe unilateral head pain, with orbital, supraorbital, temporal and/or other trigeminal distribution, lasting for 1–600 seconds and occurring as single stabs, series of stabs or in a saw-tooth pattern
- C. At least one of the following five cranial autonomic symptoms or signs, ipsilateral to the pain:
 - a. conjunctival injection and/or lacrimation
 - b. nasal congestion and/or rhinorrhoea
 - c. eyelid oedema
 - d. forehead and facial sweating
 - e. miosis and/or ptosis
- D. Occurring with a frequency of at least one a day
- E. Not better accounted for by another ICHD-3 diagnosis

SUNCT (SHORT LASTING UNILATERAL NEURALGIFORM HEADACHES WITH CONJUNCTIVAL INJECTION AND TEARING)

- A. Attacks fulfilling criteria for 3.3 *Short-lasting unilateral neuralgiform headache attacks*, and criterion B below
- B. Both of the following, ipsilateral to the pain:
 - a. conjunctival injection
 - b. lacrimation (tearing)

EPISODIC SUNCT

- A. Attacks fulfilling criteria for 3.3.1 *Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing* and occurring in bouts
- B. At least two bouts lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of ≥ 3 months

CHRONIC SUNCT

- A. Attacks fulfilling criteria for 3.3.1 *Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing*, and criterion B below
- B. Occurring without a remission period, or with remissions lasting < 3 months, for at least 1 year

SUNA (Short lasting unilateral neuralgiform headaches with cranial autonomic symptoms)

- A. Attacks fulfilling criteria for 3.3 *Short-lasting unilateral neuralgiform headache attacks*, and criterion B below
- B. Only one or neither of conjunctival injection and lacrimation (tearing)

EPISODIC SUNA

- A. Attacks fulfilling criteria for 3.3.2 *Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms* and occurring in bouts
- B. At least two bouts lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of ≥ 3 months

CHRONIC SUNA

- A. Attacks fulfilling criteria for 3.3.2 *Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms*, and criterion B below
- B. Occurring without a remission period, or with remissions lasting <3 months, for at least 1 year

Appendix 9. Differential diagnosis of The Trigeminal Autonomic Cephalalgias and Trigeminal Neuralgia

TAC	Hemicrania Continua	Cluster Headache	Paroxysmal Hemicrania	SUNA	Trigeminal neuralgia
Male / Female ratio	Female	2.5: 1	Female	Male	Female
Attack duration	Constant	15 minutes – 3 hours	5 – 30 minutes	1-600 seconds	Few seconds - 2 minutes
Attack frequency	Not applicable	Up to 8 / day	Up to 5 / hour	Up to 30 / hour	1-50 / day
Circadian features	-	++	+	-	-
Restlessness	±	++	±	±	-
Interparoxysmal pain*	NA	Yes	Yes	Yes	Yes
Other differentiating features	Typically more migrainous features than other TACs Can be potentiated by acute-relief medication overuse	Strongest association with circadian rhythm, restlessness, attacks from sleep, alcohol triggering	Spontaneous, shorter and more frequent attacks than cluster.	Attacks of pain can be spontaneous and triggered e.g. eating, brushing teeth, cold wind, neck movements. All attacks can be spontaneous. Pain is always primarily in the distribution of the ophthalmic division of the trigeminal nerve with radiation to affect	Attacks of pain can be spontaneous and always triggered e.g. eating, brushing teeth, cold wind, neck movements. Pain is always primarily in the distribution of the 2nd and 3rd division of the trigeminal nerve - should rarely affect V1 and should not affect C2 (back of head and neck) No autonomic features
Episodic or chronic tendency	Chronic	Episodic	Chronic	Chronic	Currently undefined.
	Continuous pain, without remission	Attacks occurring in periods lasting from 7 days to a year, separated by pain-free periods lasting at least three months*	Attacks occurring for more than one year without remission (remission is arbitrarily defined as three months pain free)		
Acute attack treatment	None – prone to development of	Sumatriptan 6mg subcutaneous High flow oxygen	None	None – too short	None - too short

	medication-overuse				
Preventive treatment	Indomethacin	Verapamil Prednisolone	Indomethacin	Lamotrigine	Carbamazepine

*The paroxysmal trigeminal autonomic cephalalgias can have pain between acute attacks. In most cases the interparoxysmal pain is part of the same disorder. In some cases, hemicrania continua may be co-exist. Therefore, a trial of Indomethacin could be considered⁴⁰⁵⁻⁴⁰⁷

HEMICRANIA CONTINUA

Epidemiology

Hemicrania continua is an uncommon disorder with estimated prevalence of 0.8-1.5% however it is acknowledged that this is compounded by diagnostic inaccuracy^{408,409}.

The disorder seems to be more common in women. Mean age of onset is between the 3rd and 4th decade^{410,411}.

Clinical features

Hemicrania continua is characterized by strictly unilateral pain of moderate severity with ipsilateral autonomic features which may be more prominent during exacerbations.

Hemicrania continua has both clinical and pathophysiological overlap with migraine⁴¹².

Thus, although more than half of cases can be restless during the attacks, others experience motion sensitivity^{30,410,411,413,414}.

Although the disorder is defined by chronicity it can present in a relapsing and remitting (thus episodic) form⁴¹⁵⁻⁴²⁰.

Management

There are no RCTs for preventive treatment in hemicrania continua.

Acute treatment

Medication overuse can occur in hemicrania continua. Thus, analgesics should be withdrawn prior to assessing response to indomethacin^{421,422}.

Preventive treatment

Hemicrania continua is an indomethacin-sensitive disorder. The effective dose range is between 25-300mg daily dose^{46,395-397}.

Although most patients show a rapid response to Indomethacin, some patients can take up to a week to demonstrate a response to an effective dose. Based upon this BASH recommends Indomethacin 25mg TDS for 7 days, 50mg TDS 7 days, up to 75mg TDS.

Dose requirements can change over time and some patients may go into remission⁴⁰⁰.

Therefore, once symptoms are well controlled for a period of time gradual dose reduction should be tried to maintain the lowest effective dose or, if there is no recurrence on each dose reduction, withdrawal during remission periods.

Gastrointestinal side effects with Indomethacin are common and may preclude use of the drug. A concomitant proton-pump blocker or H2-antagonist can be used.

LIST OF ABBREVIATIONS

ACE	Angiotensin converting enzyme
AHS	American Headache Society
ARB	Angiotensin receptor blocker
BASH	British Association for the Study of Headache
BD	Bis in die (<i>lat.</i> Twice daily)
CGRP	Calcitonin gene related peptide
CNS	Central nervous system
CSF	Cerebrospinal fluid
CT	Computer tomography
ECG	Electrocardiogram
EFNS	European Federation of Neurological Societies
GCA	Giant cell arteritis
GON	Greater occipital nerve
GP	General practitioner
HIT-6	Headache Impact Test 6
HIS	International Headache Society
ICHD	International Classification of Headache Disorders
IIH	Idiopathic intracranial hypertension
LP	Lumbar puncture
MG	Milligrams
MHRA	Medicines and Healthcare products Regulatory Agency
MOH	Medication overuse headache
MRI	Magnetic resonance imaging
NICE	National Institute for Health and Care Excellence
NNT	Number needed to treat
NSAID	Non-steroidal anti-inflammatory
OD	Omne in die (<i>lat.</i> Once daily)
QDS	Quater die sumendum (<i>lat.</i> Four times daily)
RCT	Randomised controlled trial
SAH	Subarachnoid haemorrhage
SIGN	Scottish Intercollegiate Guidelines Network
SPGS	Sphenopalatine ganglion stimulation
SUNA	Short lasting unilateral neuralgiform headaches with cranial autonomic symptoms
SUNCT	Short lasting unilateral neuralgiform headaches with conjunctival injection and tearing
TAC	Trigeminal autonomic cephalalgia
TDS	Ter die sumendum (<i>lat.</i> Three times daily)
TTH	Tension-type headache

REFERENCES

1. Morris Z, Whiteley WN, Longstreth WT, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. 2009;339:b3016.
2. Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. *The New England journal of medicine*. 2007;357(18):1821-1828.
3. Katzman GL, Dagher AP, Patronas NJ. Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers. *JAMA: The Journal of the American Medical Association*. 1999;282(1):36-39.
4. Locker TE, Thompson C, Rylance J, Mason SM. The utility of clinical features in patients presenting with nontraumatic headache: an investigation of adult patients attending an emergency department. *Headache*. 2006;46(6):954-961.
5. Landtblom AM, Fridriksson S, Boivie J, Hillman J, Johansson G, Johansson I. Sudden onset headache: a prospective study of features, incidence and causes. *Cephalalgia*. 2002;22(5):354-360.
6. Linn FH, Rinkel GJ, Algra A, van Gijn J. Headache characteristics in subarachnoid haemorrhage and benign thunderclap headache. *J Neurol Neurosurg Psychiatry*. 1998;65(5):791-793.
7. Hamilton W, Kernick D. Clinical features of primary brain tumours: a case-control study using electronic primary care records. *Br J Gen Pract*. 2007;57(542):695-699.
8. Sempere AP, Porta-Etessam J, Medrano V, et al. Neuroimaging in the evaluation of patients with non-acute headache. *Cephalalgia*. 2005;25(1):30-35.
9. Edlow JA, Panagos PD, Godwin SA, Thomas TL, Decker WW, Physicians ACoE. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute headache. *Ann Emerg Med*. 2008;52(4):407-436.
10. Ramirez-Lassepas M, Espinosa CE, Cicero JJ, Johnston KL, Cipolle RJ, Barber DL. Predictors of intracranial pathologic findings in patients who seek emergency care because of headache. *Arch Neurol*. 1997;54(12):1506-1509.
11. Kurth T, Buring JE, Rist PM. Headache, migraine and risk of brain tumors in women: prospective cohort study. *J Headache Pain*. 2015;16:501.
12. Kernick DP, Ahmed F, Bahra A, et al. Imaging patients with suspected brain tumour: guidance for primary care. *Br J Gen Pract*. 2008;58(557):880-885.
13. Alter M, Daube JR, Franklin G, et al. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 1994;44(7):1353-1354.
14. Ontario HQ. Neuroimaging for the evaluation of chronic headaches: an evidence-based analysis. *Ont Health Technol Assess Ser*. 2010;10(26):1-57.
15. Physicians. ACoE. Clinical policy: critical issues in the evaluation and management of patients presenting to the emergency department with acute headache. *Ann Emerg Med*. 2002;39(1):108-122.
16. Aygun D, Bildik F. Clinical warning criteria in evaluation by computed tomography the secondary neurological headaches in adults. *Eur J Neurol*. 2003;10(4):437-442.
17. Shibata T, Kubo M, Kuwayama N, Hirashima Y, Endo S. Warning headache of subarachnoid hemorrhage and infarction due to vertebrobasilar artery dissection. *Clin J Pain*. 2006;22(2):193-196.
18. Tsushima Y, Endo K. MR Imaging in the Evaluation of Chronic or Recurrent Headache. *Radiology*. 2005;235(2):575-579.
19. D'Amico D, Leone M, Bussone G. Side-locked unilaterality and pain localization in long-lasting headaches: migraine, tension-type headache, and cervicogenic headache. *Headache*. 1994;34(9):526-530.
20. Momoh-Ojewuyi A, Ayubi A, Abusamra R, et al. Side locked headaches. *The Journal of Headache and Pain*. 2013;14(Supplement 1):64.
21. Rasmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. *Cephalalgia*. 1991;11(3):129-134.
22. Iversen HK, Langemark M, Andersen PG, Hansen PE, Olesen J. Clinical characteristics of migraine and episodic tension-type headache in relation to old and new diagnostic criteria. *Headache*. 1990;30:514-519.
23. Lance JW, Anthony M. Some clinical aspects of migraine: A prospective survey of 500 patients. *Archives of Neurology*. 1966;15:356-361.
24. Kelman L. Migraine Pain Location: A Tertiary Care Study of 1283 Migraineurs. *Headache*. 2005;45(8):1038-1047.
25. Vikelis M, Rapoport AM. Cluster headache in Greece: an observational clinical and demographic study of 302 patients. *J Headache Pain*. 2016;17(1):88-97.
26. Torelli P, Cologno D, Cademartiri C, Manzoni GC. Application of the International headache classification criteria in 652 cluster headache patients. *Cephalalgia*. 2001;21(2):145-150.

27. Bahra A, May A, Goadsby PJ. Diagnostic difficulties in cluster headache. *Neurology*. 2000;54(S2):26.
28. Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: a prospective clinical study of 31 cases. *Brain*. 2008;131:1142-1155.
29. Prakash S, Belani P, Fau - Susvirkar A, Susvirkar A, Fau - Trivedi A, Trivedi A, Fau - Ahuja S, Ahuja S, Fau - Patel A, Patel A. Paroxysmal hemicrania: a retrospective study of a consecutive series of 22 patients and a critical analysis of the diagnostic criteria. *The Journal of Headache and Pain*. 2013;1414(26):1-8.
30. Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. *Brain*. 2010;133(7):1973-1986.
31. Cohen AS, Matharu MS, Goadsby PJ. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or cranial autonomic features (SUNA)--a prospective clinical study of SUNCT and SUNA. *Brain*. 2006;129(10):2746-2760.
32. Blau NJ, Dexter SL. The site of pain origin during migraine attacks. *Cephalalgia*. 1981;1:143-147.
33. Russell MB, Rasmussen BK, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. *Cephalalgia*. 1996;16:239-245.
34. Olesen J. Some clinical features of the acute migraine attack. An analysis of 750 patients. *Headache*. 1978;18:268-357.
35. Davies PT, Peatfield RC, Steiner TJ, Bond RA, Clifford Rose F. Some clinical comparisons between common and classical migraine: a questionnaire-based study. *Cephalalgia*. 1991;11(5):223-227.
36. Obermann M, Yoon MS, Dommès P, et al. Prevalence of trigeminal autonomic symptoms in migraine: a population-based study. *Cephalalgia*. 2007;27(6):504-509.
37. Ekbom K. A clinical comparison of cluster headache and migraine. *Acta Neurologica Scandinavica*. 1970;46 (suppl 41)(1).
38. Schurks M, Kurth T, de Jesus J, Jonjic M, Roskopf D, Diener HC. Cluster headache: clinical presentation, lifestyle features, and medical treatment. *Headache*. 2006;46(8):1246-1254.
39. Krymchantowski AV. Aura with non-migraine headache. *Current Pain and Headache Reports*. 2005;9(4):264-267.
40. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. *J Neurol Neurosurg Psychiatr*. 1960;23(23):23-32.
41. Kelman L. Pain characteristics of the acute migraine attack. *Headache*. 2006;46:942-953.
42. Kudrow L. *Cluster Headache: Mechanisms and Management*. Oxford: Oxford University Press; 1980.
43. Manzoni GC. Cluster headache and lifestyle: remarks on a population of 374 male patients. *Cephalalgia*. 1999;19:88-94.
44. Bahra A, May A, Goadsby PJ. Cluster Headache : A prospective clinical study with diagnostic implications. *Neurology*. 2002;58(3):354-361.
45. van Vliet JA, Eekers PJ, Haan J, Ferrari MD. Evaluating the IHS criteria for cluster headache--a comparison between patients meeting all criteria and patients failing one criterion. *Cephalalgia*. 2006;26(3):241-245.
46. Boes CJ, Dodick DW. Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients. *Headache*. 2002(8):699-708.
47. Prakash S, Patell R. Paroxysmal hemicrania: an update. *Current Pain and Headache Reports*. 2014;18(4):407.
48. Sjaastad O, Saunte C, Salveson R, et al. Shortlasting unilateral neuralgiform headache attacks with conjunctival injection, tearing, sweating and rhinorrhea. *Cephalalgia*. 1989;9:147-156.
49. Weng HY, Cohen AS, Schankin C, Goadsby PJ. Phenotypic and treatment outcome data on SUNCT and SUNA, including a randomised placebo-controlled trial. *Cephalalgia*. 2017;333102417739304.
50. Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in patients with cluster headache. *Neurology*. 2006;67(1):109-113.
51. Weber F, Knopf H. Incidental findings in magnetic resonance imaging of the brains of healthy young men. *Journal of the Neurological Sciences*. 2006;240(1-2):81-84.
52. Howard L. Are investigations anxiolytic or anxiogenic? A randomised controlled trial of neuroimaging to provide reassurance in chronic daily headache. *Journal of Neurology, Neurosurgery & Psychiatry*. 2005;76(11):1558-1564.
53. Ramirez-Lassepas M, Espinosa CE, Cicero JJ, Johnston KL, Cipolle RJ, Barber DL. Predictors of intracranial pathologic findings in patients who seek emergency care because of headache. *Archives of Neurology*. 1997;54(12):1506-1509.
54. Seymour JJ, Moscati RM, Jehle DV. Response of headaches to nonnarcotic analgesics resulting in missed intracranial hemorrhage. *Am J Emerg Med*. 1995;13(1):43-45.
55. Pfadenhauer K, Schönsteiner T, Keller H. The risks of sumatriptan administration in patients with unrecognized subarachnoid haemorrhage (SAH). *Cephalalgia*. 2006;26(3):320-323.
56. Rothrock J. The perils of misinterpreting a treatment response. *Headache*. 2005;45(5):599-600.
57. Agostoni E. Headache in cerebral venous thrombosis. *Neurol Sci*. 2004;25 Suppl 3:S206-210.
58. Abisaab J, Nevadunsky N, Flomenbaum N. Emergency department presentation of bilateral carotid artery dissections in a postpartum patient. *Ann Emerg Med*. 2004;44(5):484-489.
59. Leira EC, Cruz-Flores S, Leacock RO, Abdulrauf SI. Sumatriptan can alleviate headaches due to carotid artery dissection. *Headache*. 2001;41(6):590-591.
60. Lipton RB, Mazer C, Newman LC, Solomon S. Sumatriptan relieves migrainelike headaches associated with carbon monoxide exposure. *Headache*. 1997;37(6):392-395.
61. Vázquez-Barquero A, Ibáñez FJ, Herrera S, Izquierdo JM, Berciano J, Pascual J. Isolated headache as the presenting clinical manifestation of intracranial tumors: a prospective study. *Cephalalgia*. 1994;14(4):270-272.
62. Tepper SJ, Dahlöf CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. *Headache*. 2004;44(9):856-864.
63. Linn FH, Wijdicks EF, van der Graaf Y, Weerdesteyn-van Vliet FA, Bartelds AI, van Gijn J. Prospective study of sentinel headache in aneurysmal subarachnoid haemorrhage. *Lancet*. 1994;344(8922):590-593.
64. Morgenstern LB, Luna-Gonzales H, Huber JC, et al. Worst headache and subarachnoid hemorrhage: prospective, modern computed

- tomography and spinal fluid analysis. *Ann Emerg Med.* 1998;32(3 Pt 1):297-304.
65. Perry JJ, Stiell IG, Sivilotti ML, et al. Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage: prospective cohort study. *BMJ.* 2011;343:d4277.
 66. Backes D, Rinkel GJ, Kemperman H, Linn FH, Vergouwen MD. Time-dependent test characteristics of head computed tomography in patients suspected of nontraumatic subarachnoid hemorrhage. *Stroke.* 2012;43(8):2115-2119.
 67. Stewart H, Reuben A, McDonald J. LP or not LP, that is the question: gold standard or unnecessary procedure in subarachnoid haemorrhage? *Emerg Med J.* 2014;31(9):720-723.
 68. Mark DG, Hung YY, Offerman SR, et al. Nontraumatic subarachnoid hemorrhage in the setting of negative cranial computed tomography results: external validation of a clinical and imaging prediction rule. *Ann Emerg Med.* 2013;62(1):1-10.e11.
 69. Blok KM, Rinkel GJ, Majoie CB, et al. CT within 6 hours of headache onset to rule out subarachnoid hemorrhage in nonacademic hospitals. *Neurology.* 2015;84(19):1927-1932.
 70. Cruickshank A, Auld P, Beetham R, et al. Revised national guidelines for analysis of cerebrospinal fluid for bilirubin in suspected subarachnoid haemorrhage. *Ann Clin Biochem.* 2008;45(Pt 3):238-244.
 71. Fishman R. *Cerebral Fluid in Diseases of the Nervous System.* WB Saunders; 1980.
 72. Morgan CJ, Pyne-Geithman GJ, Jauch EC, et al. Bilirubin as a cerebrospinal fluid marker of sentinel subarachnoid hemorrhage: a preliminary report in pigs. *J Neurosurg.* 2004;101(6):1026-1029.
 73. Perry JJ, Spacek A, Forbes M, et al. Is the combination of negative computed tomography result and negative lumbar puncture result sufficient to rule out subarachnoid hemorrhage? *Ann Emerg Med.* 2008;51(6):707-713.
 74. Luda E, Comitangelo R, Sicuro L. The symptom of headache in emergency departments. The experience of a neurology emergency department. *Ital J Neurol Sci.* 1995;16(5):295-301.
 75. Jaiser SR, Raman A, Maddison P. Cerebral venous sinus thrombosis as a rare cause of thunderclap headache and nonaneurysmal subarachnoid haemorrhage. *J Neurol.* 2008;255(3):448-449.
 76. Cortez O, Schaeffer CJ, Hatem SF, Glauser J, Ahmed M. Cases from the Cleveland Clinic: cerebral venous sinus thrombosis presenting to the emergency department with worst headache of life. *Emerg Radiol.* 2009;16(1):79-82.
 77. de Bruijn SF, Stam J, Kappelle LJ. Thunderclap headache as first symptom of cerebral venous sinus thrombosis. *Lancet.* 1996;348:1623-1625.
 78. Tang-Wai DF, Phan TG, Wijdicks EF. Hypertensive encephalopathy presenting with thunderclap headache. *Headache.* 2001;41(2):198-200.
 79. Heo YE, Kwon HM, Nam HW. Thunderclap headache as an initial manifestation of pheochromocytoma. *Cephalalgia.* 2009;29(3):388-390.
 80. Biousse V, Woimant F, Amarenco P, Touboul PJ, Bousser MG. Pain as the only manifestation of internal carotid artery dissection. *Cephalalgia.* 1992;12(5):314-317.
 81. Cox LK, Bertorini T, Laster RE. Headaches due to spontaneous internal carotid artery dissection magnetic resonance imaging evaluation and follow up. *Headache.* 1991;31(1):12-16.
 82. Fisher CM. The headache and pain of spontaneous carotid dissection. *Headache.* 1982;22(2):60-65.
 83. Joo IS, Lee JS. Dissecting aneurysm of the basilar artery as a cause of orgasmic headache. *Headache.* 2005;45(7):956-959.
 84. Arnold M, Camus-Jacqmin M, Stapf C, et al. Postpartum cervicocephalic artery dissection. *Stroke.* 2008;39(8):2377-2379.
 85. Buyle M, Engelborghs S, Kunnen J, De Deyn PP. Headache as only symptom in multiple cervical artery dissection. *Headache.* 2001;41(5):509-511.
 86. Dodick DW, Wijdicks EF. Pituitary apoplexy presenting as a thunderclap headache. *Neurology.* 1998;50(5):1510-1511.
 87. Cryer RJ, Ferriman D. Pituitary apoplexy. *Proc R Soc Med.* 1971;64(3):301-302.
 88. Garza I, Kirsch J. Pituitary apoplexy and thunderclap headache. *Headache.* 2007;47(3):431-432.
 89. Epstein S, Pimstone BL, De Villiers JC, Jackson WP. Pituitary apoplexy in five patients with pituitary tumours. *Br Med J.* 1971;2(5756):267-270.
 90. Espinosa PS, Choudry B, Wilbourn R, Espinosa PH, Vaishnav AG. Pituitary apoplexy: a neurological emergency case report. *J Ky Med Assoc.* 2007;105(11):538-540.
 91. Kuzma BB, Goodman JM. Sudden headache with pituitary infarction. *Surg Neurol.* 1999;52(5):532-533.
 92. He RH. [Acute pituitary vascular accident (pituitary apoplexy)]. *Zhonghua Nei Ke Za Zhi.* 1983;22(4):228-230.
 93. Asakura H, Hayashi Z, Seto M, Araki T. Spontaneous intracranial hypotension during pregnancy. *Obstet Gynecol.* 2001;97(5 Pt 2):804-805.
 94. Broadley SA, Park N, Renowden S, Ferguson IT. Unusual cause of sudden onset headache: spontaneous intracranial hypotension. *Emerg Med Australas.* 2005;17(5-6):520-523.
 95. Vaidhyanath R, Kenningham R, Khan A, Messios N. Spontaneous intracranial hypotension: a cause of severe acute headache. *Emerg Med J.* 2007;24(10):739-741.
 96. Balgera R, Rigamonti A, Sozzi G, Agostoni E. An atypical case of spontaneous intracranial hypotension. *Neurol Sci.* 2009;30(1):71-73.
 97. Ferrante E, Savino A. Thunderclap headache caused by spontaneous intracranial hypotension. *Neurol Sci.* 2005;26 Suppl 2:s155-157.
 98. Famularo G, Minisola G, Gigli R. Thunderclap headache and spontaneous intracranial hypotension. *Headache.* 2005;45(4):392-393; author reply 393.
 99. Wang SJ, Fuh JL. Exertional but not postural headache resulting from spontaneous intracranial hypotension. *Acta Neurol Taiwan.* 2005;14(1):36-37.
 100. Schievink WI, Wijdicks EF, Meyer FB, Sonntag VK. Spontaneous intracranial hypotension mimicking aneurysmal subarachnoid hemorrhage. *Neurosurgery.* 2001;48(3):516-517.
 101. Devenney E, Neale H, Forbes RB. A systematic review of causes of sudden and severe headache (Thunderclap Headache): should lists be evidence based? *J Headache Pain.* 2014;15:49.
 102. Mokri B. Spontaneous cerebrospinal fluid leaks: from intracranial hypotension to cerebrospinal fluid hypovolemia--evolution of a concept. *Mayo Clin Proc.* 1999;74(11):1113-1123.

103. Schievink WI. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. *JAMA*. 2006;295(19):2286-2296.
104. Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. *Lancet Neurol*. 2011;10(7):626-636.
105. Group. GNDC. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Neurology*. 2017;17:877-897.
106. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. *Cephalalgia*. 2007;27(3):193-210.
107. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. *Headache*. 1994;34(6):319-328.
108. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationship to age, gender and ethnicity. *Cephalalgia*. 2003;23(7):519-527.
109. Stewart WF, Schechter A, Rasmussen BK. Migraine Prevalence. A review of population-based studies. *Neurology*. 1994;44(S17-23).
110. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. *Cephalalgia*. 2004;24(6):483-490.
111. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. *Cephalalgia*. 2010;30(5):599-609.
112. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). *Cephalalgia*. 2011;31(3):301-315.
113. Victor TW, Hu X, Campbell J, White RE, Buse DC, Lipton RB. Association between migraine, anxiety and depression. *Cephalalgia*. 2010;30(5):567-575.
114. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. *Lancet Neurol*. 2004;3(8):475-483.
115. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity: disability, pain intensity, and attack frequency and duration. *Neurology*. 1994;44(suppl 4):S24-39.
116. Lipton RB, Goadsby PJ, Sawyer JP, Blakeborough P, Stewart WF. Migraine: Diagnosis and assessment of disability. *Reviews in Contemporary Pharmacotherapy*. 2000;11(2):63-73.
117. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. *Neurology*. 2003;61(3):375-382.
118. Giffin NJ, Ruggiero L, Fau - Lipton RB, Lipton Rb Fau - Silberstein SD, et al. Premonitory symptoms in migraine: an electronic diary study. (1526-632X (Electronic)).
119. Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The migraine prodrome: An electronic diary study. *Neurology*. 2016;87(3):309-313.
120. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine. *International Journal of Epidemiology*. 1995;24(3):612-618.
121. Rasmussen BK, Olesen J. Migraine with and without aura: an epidemiological study. *Cephalalgia*. 1992;12(4):221-228.
122. Dodick D. Diagnosing headache: clinical clues and clinical rules. *Advanced Studies in Medicine*. 2003;3(2):87-92.
123. Rothrock JF, Parada VA, Sims C, Key K, Walters NS, Zweifler RM. The impact of intensive patient education on clinical outcome in a clinic-based migraine population. *Headache*. 2006;46(5):726-731.
124. Gaul C, Lieserling-Latta E, Schafer B, Fritsche G, Holle D. Integrated multidisciplinary care of headache disorders: A narrative review. *Cephalalgia*. 2016;36(12):1181-1191.
125. Laughey WF, Holmes WF, MacGregor AE, Sawyer JPC. Headache consultation and referral patterns in one UK general practice. *Cephalalgia*. 1999;19(4):328-329.
126. Kindelan-Calvo P, Gil-Martínez A, Paris-Aleman A, et al. Effectiveness of therapeutic patient education for adults with migraine. A systematic review and meta-analysis of randomized controlled trials. *Pain Med*. 2014;15(9):1619-1636.
127. Seng EK, Holroyd KA. Behavioral migraine management modifies behavioral and cognitive coping in people with migraine. *Headache*. 2014;54(9):1470-1483.
128. Lipton RB, Stewart WF, Stone AM. Stratified care vs step care strategies for migraine : results of the Disability in Strategies of Care (DISC) Study. *JAMA*. 2000;284(20):754-763.
129. Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. *Pharmacoeconomics*. 2002;20(2):91-100.
130. Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. *European Journal of Clinical Pharmacology*. 1983;24(6):777-785.
131. Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. *Cephalalgia*. 1983;4(4):253-263.
132. Tokola RA. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. *Cephalalgia*. 1988;8(3):139-147.
133. MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. *Cephalalgia*. 1993;13(2):124-127.
134. Edmeads J. Defining response in migraine: which endpoints are important? *Eur Neurol*. 2005;53 Suppl 1:22-28.
135. Dahlof CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials. *Cephalalgia*. 2006;26(2):98-106.
136. Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. *Cochrane Database Syst Rev*. 2014(5):Cd009108.
137. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during migraine aura. *Neurology*. 1994;44(9):1587-1592.
138. Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. *European Journal of Neurology*. 2004;11(10):671-677.
139. Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. *Cochrane Database Syst Rev*. 2012;2(1469-493X (Electronic)):CD009663.

140. Dahlöf CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials. *Cephalalgia*. 2006;26(2):98-106.
141. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. *Neurology*. 2002;59(7):1011-1014.
142. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. *J Emerg Med*. 2002;23(2):141-148.
143. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. *Headache*. 2015;55(1):3-20.
144. Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*. 2013(4):CD008041.
145. Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. *Cephalalgia*. 2004;24(11):947-954.
146. Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for the treatment of acute migraine. *Headache*. 2005;45(4):283-292.
147. MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. *Headache*. 2002;42(4):249-255.
148. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. *Headache*. 2005;45(8):973-982.
149. Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*. 2013(4):CD008783.
150. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. *Cephalalgia*. 1999;19(4):232-240.
151. McNeely W, Goa KL. Diclofenac-potassium in migraine: a review. *Drugs*. 1999;57(6):991-1003.
152. Dahlöf C, Björkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. *Cephalalgia*. 1993;13(2):117-123.
153. Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*. 2013(4):CD008039.
154. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. *Cephalalgia*. 1992;12(3):169-171; discussion 128.
155. Havanka-Kanniainen H. Treatment of acute migraine attack: ibuprofen and placebo compared. *Headache*. 1989;29(8):507-509.
156. Mainardi F, Maggioni F, Pezzola D, Zava D, Zanchin G. Dexketoprofen trometamol in the acute treatment of migraine attack: a phase II, randomized, double-blind, crossover, placebo-controlled, dose optimization study. *J Pain*. 2014;15(4):388-394.
157. Dib M, Massiou H, Weber M, et al. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. *Neurology*. 2002;58(11):1660-1665.
158. Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*. 2013(10):CD009455.
159. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. *Cephalalgia*. 1985;5(1):5-10.
160. Sargent JD, Baumel B, Peters K, et al. Aborting a migraine attack: naproxen sodium v ergotamine plus caffeine. *Headache*. 1988;28(4):263-266.
161. Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. *Cochrane Database Syst Rev*. 2013(4):CD008040.
162. Myllylä VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. *Headache*. 1998;38(3):201-207.
163. Kelly AM, Walcynski T, Gunn B. The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis. *Headache*. 2009;49(9):1324-1332.
164. Friedman BW, Esses D, Solorzano C, et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. *Ann Emerg Med*. 2008;52(4):399-406.
165. Sharma S, Prasad A, Nehru R, et al. Efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine. *Headache*. 2002;42(9):896-902.
166. Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. *Ann Emerg Med*. 2011;57(5):475-482.e471.
167. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. *Cephalalgia*. 1984;4(2):107-111.
168. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. *Cephalalgia*. 2000;20(6):588-596.
169. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. *Cephalalgia*. 2008;28(4):383-391.
170. Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. *European Neurology*. 2002;47(2):99-107.
171. Poolsup N, Leelasangkaluk V, Jittangtrong J, Rithlamlert C, Ratanapantamane N, Khanthong M. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. *J Clin Pharm Ther*. 2005;30(6):521-532.
172. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. *Headache*. 1997;37(10):640-645.
173. Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. *Cephalalgia*. 1999;19(5):525-530.

174. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. *JAMA*. 2007;297(13):1443-1454.
175. Loder E, Freitag FG, Adelman J, Pearlmand S, Abu-Shakra S. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. *Curr Med Res Opin*. 2005;21(3):381-389.
176. Spierings EL, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. *CNS Drugs*. 2004;18(15):1133-1141.
177. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. *CNS Drugs*. 2005;19(2):125-136.
178. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. *Cochrane Database Syst Rev*. 2016;4:CD008541.
179. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT_{1B/1D} agonists) in acute migraine treatment: a meta-analysis of 53 trials. *Lancet*. 2001;358(9294):1668-1675.
180. Evers S, Savi L, Omboni S, Lisotto C, Zanchin G, Pinessi L. Efficacy of frovatriptan as compared to other triptans in migraine with aura. *J Headache Pain*. 2015;16:514.
181. Cortelli P, Allais G, Tullo V, et al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. *Neurol Sci*. 2011;32 Suppl 1:S95-98.
182. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT₁ agonists) in the acute treatment of migraine. *Headache*. 2004;44(5):414-425.
183. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. *Cephalalgia*. 2006;26(10):1192-1198.
184. Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2007;6(12):1054-1062.
185. Albsoul-Younes AM, Salem HA, Ajlouni SF, Al-Safi SA. Topiramate slow dose titration: improved efficacy and tolerability. *Pediatr Neurol*. 2004;31(5):349-352.
186. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. *Qual Life Res*. 2003;12(8):963-974.
187. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. *Arch Neurol*. 1987;44(5):486-489.
188. Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. *BMJ*. 2010;341:c5222.
189. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. *Arch Neurol*. 1979;36(11):695-699.
190. Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. *Arch Neurol*. 1993;50(8):825-830.
191. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. *Clin Ther*. 2009;31(3):542-559.
192. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. *JAMA*. 2003;289(1):65-69.
193. Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. *Cephalalgia*. 2014;34(7):523-532.
194. Linde K, Rosnagel K. Propranolol for migraine prophylaxis. *Cochrane Database Syst Rev*. 2004(2):CD003225.
195. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. *Cephalalgia*. 1989;9(4):247-253.
196. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. *Headache*. 2001;41(10):968-975.
197. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. *JAMA*. 2004;291(8):965-973.
198. Silberstein SD, Neto W, Schmitt J, Jacobs D, Group M-S. Topiramate in migraine prevention: results of a large controlled trial. *Arch Neurol*. 2004;61(4):490-495.
199. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. *Cephalalgia*. 2007;27(7):814-823.
200. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. *Cephalalgia*. 2003;23(8):820-824.
201. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. *Headache*. 2007;47(2):170-180.
202. Diener HC, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. *J Neurol*. 2004;251(8):943-950.
203. Guo Y, Han X, Yu T, Yao G. Meta-analysis of efficacy of topiramate in migraine prophylaxis. *Neural Regen Res*. 2012;7(23):1806-1811.
204. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. *Cochrane Database Syst Rev*. 2013(6):CD010610.
205. Donegan S, Dixon P, Hemming K, Tudur-Smith C, Marson A. A systematic review of placebo-controlled trials of topiramate: How useful is a multiple-indications review for evaluating the adverse events of an antiepileptic drug? *Epilepsia*. 2015;56(12):1910-1920.
206. Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. *N Engl J Med*. 2017;377(22):2123-2132.
207. Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. *Cephalalgia*. 2018;38(6):1026-1037.
208. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind,

- placebo-controlled, phase 3b study. *Lancet*. 2018;392(10161):2280-2287.
209. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol*. 2017;16(6):425-434.
 210. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. *N Engl J Med*. 2017;377(22):2113-2122.
 211. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. *Neurology*. 2018;91(24):e2211-e2221.
 212. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. *JAMA Neurol*. 2018;75(9):1080-1088.
 213. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. *Cephalalgia*. 2018;38(8):1442-1454.
 214. Aurora SK, Dodick Dw Fau - Turkel CC, Turkel Cc Fau - DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. *Cephalalgia*. 2010.
 215. Diener HC, Dodick Dw Fau - Aurora SK, Aurora Sk Fau - Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia*. 2010;30(7):804-814.
 216. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache*. 2010;50(6):921-936.
 217. Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. *J Headache Pain*. 2014;15:54.
 218. NICE Technology Appraisal guidance 260 (2012) Botulinum Toxin Type A in the prevention of headache in adults with Chronic Migraine. <http://publications.nice.org.uk/botulinum-toxin-type-a-for-the-prevention-of>. Published 2012. Accessed.
 219. Linde K, Allais G, Brinkhaus B, et al. Acupuncture for the prevention of episodic migraine. *Cochrane Database Syst Rev*. 2016(6):CD001218.
 220. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. *BMJ*. 2001;322(7277):19-22.
 221. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine : a double-blind study versus placebo. *Cephalalgia*. 1992;12:81-84.
 222. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. *Cephalalgia*. 1997;17:103-108.
 223. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. *Neurology*. 2002;58(11):1652-1659.
 224. Kaniecki RG. A comparison of Divalproex with propranolol and placebo for the prophylaxis of migraine without aura. *Archives of Neurology*. 1997;54:1141-1145.
 225. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. *Clin Neuropharmacol*. 2005;28(6):277-279.
 226. Mitsikostas DD, Polychronidis I. Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial. *Funct Neurol*. 1997;12(5):267-276.
 227. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. *Cochrane Database Syst Rev*. 2013(6):CD010611.
 228. Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. *Cephalalgia*. 1984;4(2):91-96.
 229. Olsson JE, Behring HC, Forssman B, et al. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study. *Acta Neurol Scand*. 1984;70(3):160-168.
 230. Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dose ranging followup. *Headache*. 1988;28:15-23.
 231. Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. *Headache*. 1986;26(10):490-493.
 232. Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. *Acta Neurol Scand*. 1984;69(1):1-8.
 233. Johannsson V, Nilsson LR, Widelius T, et al. Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. *Headache*. 1987;27(7):372-374.
 234. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. *Headache*. 1981;21(6):235-239.
 235. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. *Cephalalgia*. 2002;22(3):209-221.
 236. Lücking CH, Oestreich W, Schmidt R, Soyka D. Flunarizine vs. propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. *Cephalalgia*. 1988;8 Suppl 8:21-26.
 237. Ashkenazi A, Matro R, Shaw JW, Abbas MA, Silberstein SD. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study. *J Neurol Neurosurg Psychiatry*. 2008;79(4):415-417.
 238. Cuadrado ML, Aledo-Serrano A, Navarro P, et al. Short-term effects of greater occipital nerve blocks in chronic migraine: A double-blind, randomised, placebo-controlled clinical trial. *Cephalalgia*. 2017;37(9):864-872.
 239. Inan LE, Inan N, Karadas O, et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. *Acta Neurol Scand*. 2015;132(4):270-277.
 240. Dilli E, Halker R, Vargas B, et al. Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study. *Cephalalgia*. 2015;35(11):959-968.
 241. Schoenen J, Vandermismissen B, Jeanette S, et al. Migraine prevention with a supraorbital

- transcutaneous stimulator: a randomized controlled trial. *Neurology*. 2013;80(8):697-704.
242. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. *Lancet Neurol*. 2010;9(4):373-380.
243. Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. *Neurology*. 2016;87(5):529-538.
244. Sándor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. *Neurology*. 2005;64(4):713-715.
245. Köseoglu E, Talaslioglu A, Gönül AS, Kula M. The effects of magnesium prophylaxis in migraine without aura. *Magnes Res*. 2008;21(2):101-108.
246. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. *Neurology*. 1998;50(2):466-470.
247. MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: a pilot study. *Cephalalgia*. 1990;10(6):305-310.
248. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. *Headache*. 1993;33(7):385-389.
249. MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey--Phase III. *Curr Med Res Opin*. 2004;20(7):1143-1150.
250. Vetvik KG, MacGregor EA, Lundqvist C, Russell MB. Self-reported menstrual migraine in the general population. *J Headache Pain*. 2010;11(2):87-92.
251. Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. *Cephalalgia*. 2003;23(4):302-308.
252. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. *Neurology*. 2000;55(10):1517-1523.
253. Wöber C, Brannath W, Schmidt K, et al. Prospective analysis of factors related to migraine attacks: the PAMINA study. *Cephalalgia*. 2007;27(4):304-314.
254. Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. *Curr Opin Neurol*. 2008;21(3):331-337.
255. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. *Neurology*. 2004;63(2):261-269.
256. Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. *Cephalalgia*. 2009;29(11):1133-1148.
257. Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. *CNS Drugs*. 2008;22(10):877-886.
258. Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. *Headache*. 2007;47(7):1037-1049.
259. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. *Headache*. 2001;41(3):248-256.
260. de Lignières B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. *Br Med J (Clin Res Ed)*. 1986;293(6561):1540.
261. Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: A double-blind trial of percutaneous estradiol. *Gynecological Endocrinology*. 1988;2(2):113-120.
262. Pradalier A, Vincent D, Beaulieu P, Baudesson G, Launay J. Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In: Proceedings of the 10th Migraine Trust Symposium 1994:129-132.
263. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. *Neurology*. 2006;67(12):2159-2163.
264. Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women. *Neurology*. 2005;64:1020-1026.
265. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Napp G. Migraine with aura and reproductive life events: a case control study. *Cephalalgia*. 2000;20(8):701-707.
266. Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: a prospective study. *Cephalalgia*. 2003;23(3):197-205.
267. MacGregor EA. Migraine in pregnancy and lactation. *Neurol Sci*. 2014;35 Suppl 1:61-64.
268. Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. *Headache*. 2014;54(7):1158-1172.
269. Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. *Headache*. 2015;55(4):490-501.
270. Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. *Cephalalgia*. 2018;38(6):1081-1092.
271. Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. *Eur J Epidemiol*. 2013;28(9):759-769.
272. Diener H-C, Dahlof C. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. *The Headaches*. Vol 871-878. Philadelphia: Lippincott Williams & Wilkins; 1999.
273. Scher AI, Stewart WF, Lieberman J, Lipton RB. Prevalence of frequent headache in a population sample. *Headache*. 1997;37:330.
274. Castillo J, Munoz P Fau - Guitera V, Guitera V Fau - Pascual J, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. *Headache*. 1999;39(1526-4610 (Electronic)):190-196.
275. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors and biannual follow-up. *Neurology*. 2000;54(2):314-319.
276. Westergaard ML, Hansen EH, Glümer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. *Cephalalgia*. 2014;34(6):409-425.
277. Wolfson WQ, Graham JR. Development of tolerance to ergot alkaloids in a patient with unusually severe migraine. *The New England Journal of Medicine*. 1949;241(8):296-298.

278. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular analgesic use? *Headache*. 2003;43(3):179-190.
279. Peters GA, Horton BT. Headache: With special reference to the excessive use of ergotamine preparations and withdrawal effects. *Proceedings of the Staff Meetings of the Mayo Clinic*. 1951;26(9):153-161.
280. Rowsell AR, Neylan C, Wilkinson M. Ergotamine induced headaches in migrainous patients. *Headache*. 1973;13:65-67.
281. Wainscott G, Volans G, Wilkinson M. Ergotamine-induced headache. *British Medical Journal*. 1974;36:24.
282. Saper JR. Ergotamine dependancy - a review. *Headache*. 1987;27(8):435-438.
283. Anderson PG. Ergotamine headache. *Headache*. 1975;15:118-121.
284. Limmroth V, S K, Fritsche G, Diener H-C. Headache after frequent use of new serotonin agonists zolmitriptan and naratriptan. *Lancet*. 1999;353:378.
285. Kaube H, May A, Pfaffenrath V. Sumatriptan [letter; comment]. *Bmj*. 1994;308(6943):1573-1574.
286. Mathew NT, Kurman R, Perez F. Drug-induced refractory headache - clinical features and management. *Headache*. 1990;30:634-638.
287. Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headaches de novo. *Headache*. 1988;28:61-62.
288. Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J. Analgesic overuse among subjects with headache, neck, and low-back pain. *Neurology*. 2004;62(9):1540-1544.
289. Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M. Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache. *Eur J Pain*. 2005;9(3):285-291.
290. Radat F, Lanteri-Minet M. What is the role of dependence-related behavior in medication-overuse headache? *Headache*. 2010;50(10):1597-1611.
291. Merikangas KR, Angst J, Isler H. Migraine and psychopathology : Results of the Zurich cohort study of young adults. *Archives of General Psychiatry*. 1990;47:849-853.
292. Dodick DW, Silberstein SD. How clinicians can detect, prevent and treat medication overuse headache. *Cephalalgia*. 2008;28(11):1207-1217.
293. Grande RB, Aaseth K, Benth J, Lundqvist C, Russell MB. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. *Eur J Neurol*. 2011;18(1):129-137.
294. Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. *Cephalalgia*. 2006;26(9):1097-1105.
295. Rabe K, Pageler L, Gaul C, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. *Cephalalgia*. 2013;33(3):202-207.
296. Bøe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. *Neurology*. 2007;69(1):26-31.
297. Pageler L, Katsarava Z, Limmroth V, Diener H-C. Prednisolone in the treatment of medication withdrawal headache following medication overuse headache: a placebo-controlled, double-blind and randomised pilot study. *Cephalalgia*. 2004;24(9):792.
298. Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. *Headache*. 2007;47(1):13-21.
299. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. *Neurology*. 2006;66(12):1894-1898.
300. Rossi P, Jensen R, Nappi G, Allena M, Consortium C. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. *J Headache Pain*. 2009;10(6):407-417.
301. Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. *Cephalalgia*. 2014;34(9):645-655.
302. Krymchantowski A, Moreira P. Out-patient detoxification in chronic migraine: comparison of strategies. *Cephalalgia*. 2003;23(10):982-993.
303. Silverman K, Evans SM, Strain EC, al. e. Withdrawal syndrome after double-blind cessation of caffeine consumption. *New England Journal of Medicine*. 1992;327(16):1109.
304. van Dusseldorp M, Martijn BK. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double-blind trial. *British Medical Journal*. 1990;300:1558-1559.
305. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. *Neurology*. 2001;57(9):1694-1698.
306. Kudrow L. Paradoxical effects of frequent analgesic use. *Advances in Neurology*. 1982;33:335-341.
307. Fritsche G, Diener HC. Medication overuse headaches -- what is new? *Expert Opin Drug Saf*. 2002;1(4):331-338.
308. Katsarava Z, Meussig M, Dzagnidze A, Fritsche G, Diener H-C, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4 year prospective study. *Cephalalgia*. 2005;25(1):12-15.
309. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression (or for chronic daily headaches)--clinical lessons. *Headache*. 2006;46(Suppl 3):S144-146.
310. Rossi P, Faroni JV, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. *Cephalalgia*. 2008;28(11):1196-1200.
311. Olesen J. Detoxification for medication overuse headache is the primary task. *Cephalalgia*. 2012;32(5):420-422.
312. Cevoli S, Giannini G, Favoni V, et al. Treatment of withdrawal headache in patients with medication overuse headache: a pilot study. *J Headache Pain*. 2017;18(1):56.
313. Rossi P, Faroni JV, Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. *Eur J Neurol*. 2011;18(3):396-401.
314. Ferrante T, Manzoni GC, Russo M, et al. Prevalence of tension-type headache in adult general population: the PACE study and review of the literature. *Neurol Sci*. 2013;34 Suppl 1:S137-138.

315. Yu S, Han X. Update of chronic tension-type headache. *Curr Pain Headache Rep*. 2015;19(1):469.
316. Kong X, Chen J, Jiang H, et al. Testing of diagnosis criteria of tension-type headache: A multicenter clinical study. *Cephalalgia*. 2018;333102418759784.
317. Ulrich V, Russell MB, Jensen R, Olesen J. A comparison of tension-type headache in migraineurs and in non-migraineurs: a population-based study. *Pain*. 1996;67(2-3):501-506.
318. Rasmussen BK, Jensen R, Schroll M, Olesen J. Interrelations between migraine and tension-type headache in the general population. *Arch Neurol*. 1992;49(9):914-918.
319. Lipton RB, Cady RK, Stewart WF, Wilks P, Hall C. Diagnostic lessons from the Spectrum Study. *Neurology*. 2002;58(Suppl 6):S27-S31.
320. Cady RK, Gutterman D, Saiers JA, Beach ME. Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. *Cephalalgia*. 1997;17(5):588-590.
321. Prior MJ, Cooper KM, May LG, Bowen DL. Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial. *Cephalalgia*. 2002;22(9):740-748.
322. Pini LA, Del Bene E, Zanchin G, et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium. *J Headache Pain*. 2008;9(6):367-373.
323. Stephens G, Derry S, Moore RA. Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults. *Cochrane Database Syst Rev*. 2016(6):CD011889.
324. Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of tension headache. A double-blind, placebo controlled study. *Headache*. 1987;27(2):90-95.
325. Derry S, Wiffen PJ, Moore RA. Aspirin for acute treatment of episodic tension-type headache in adults. *Cochrane Database Syst Rev*. 2017;1:CD011888.
326. Diamond S, Baltes BJ. Chronic tension headache--treated with amitriptyline--a double-blind study. *Headache*. 1971;11(3):110-116.
327. Pfaffenrath V, Diener HC, Isler H, et al. Efficacy and tolerability of amitriptylinoxide in the treatment of chronic tension-type headache: a multi-centre controlled study. *Cephalalgia*. 1994;14(2):149-155.
328. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. *J Neurol Neurosurg Psychiatry*. 1996;61(3):285-290.
329. Holroyd KA, O'Donnell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson BW. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. *Jama*. 2001;285(17):2208-2215.
330. Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. *Cochrane Database Syst Rev*. 2005(3):CD002919.
331. Diamond S. Ibuprofen versus aspirin and placebo in the treatment of muscle contraction headache. *Headache*. 1983;23(5):206-210.
332. Kubitzek F, Ziegler G, Gold MS, Liu JM, Ionescu E. Low-dose diclofenac potassium in the treatment of episodic tension-type headache. *Eur J Pain*. 2003;7(2):155-162.
333. Derry S, Wiffen PJ, Moore RA, Bendtsen L. Ibuprofen for acute treatment of episodic tension-type headache in adults. *Cochrane Database Syst Rev*. 2015(7):CD011474.
334. van Gerven JM, Schoemaker RC, Jacobs LD, et al. Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary. *Br J Clin Pharmacol*. 1996;42(4):475-481.
335. Steiner TJ, Lange R. Ketoprofen (25 mg) in the symptomatic treatment of episodic tension-type headache: double-blind placebo-controlled comparison with acetaminophen (1000 mg). *Cephalalgia*. 1998;18(1):38-43.
336. Dahlöf CG, Jacobs LD. Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. *Cephalalgia*. 1996;16(2):117-123.
337. Mehlisch DR, Weaver M, Fladung B. Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. *Headache*. 1998;38(8):579-589.
338. Veys L, Derry S, Moore RA. Ketoprofen for episodic tension-type headache in adults. *Cochrane Database Syst Rev*. 2016;9:CD012190.
339. Miller DS, Talbot CA, Simpson W, Korey A. A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. *Headache*. 1987;27(7):392-396.
340. Tavola T, Gala C, Conte G, Invernizzi G. Traditional Chinese acupuncture in tension-type headache: a controlled study. *Pain*. 1992;48(3):325-329.
341. White AR, Resch KL, Chan JC, et al. Acupuncture for episodic tension-type headache: a multicentre randomized controlled trial. *Cephalalgia*. 2000;20(7):632-637.
342. Melchart D, Streng A, Hoppe A, et al. Acupuncture in patients with tension-type headache: randomised controlled trial. *BMJ*. 2005;331(7513):376-382.
343. Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for tension-type headache. *Cochrane Database Syst Rev*. 2009(1):Cd007587.
344. Endres HG, Böwing G, Diener HC, et al. Acupuncture for tension-type headache: a multicentre, sham-controlled, patient-and observer-blinded, randomised trial. *J Headache Pain*. 2007;8(5):306-314.
345. Fink M, Gutenbrunner C, Rollnik J, Karst M. Credibility of a newly designed placebo needle for clinical trials in acupuncture research. *Forsch Komplementarmed Klass Naturheilkd*. 2001;8(6):368-372.
346. Melchart D, Linde K, Streng A, et al. Acupuncture Randomized Trials (ART) in patients with migraine or tension-type headache--design and protocols. *Forsch Komplementarmed Klass Naturheilkd*. 2003;10(4):179-184.
347. Linde K, Allais G, Brinkhaus B, et al. Acupuncture for the prevention of tension-type headache. *Cochrane Database Syst Rev*. 2016;4:CD007587.
348. Sjaastad O. *Cluster headache syndrome*. London: W.B. Saunders; 1992.
349. Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. *Brain*. 1997;120(Pt 1):193-209.
350. van Vliet JA, Eekers JA, Haan J, Ferrari MDftDRsg. Features involved in the diagnostic

- delay of cluster headache. *Journal of Neurology, Neurosurgery and Psychiatry*. 2003;74(1123-5).
351. Bahra A, Goadsby PJ. Diagnostic delays and mis-management in cluster headache. *Acta Neurologica Scandinavica*. 2004;109(3):175-179.
352. Fischera M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. *Cephalalgia*. 2008;28(6):614-618.
353. Friedman AP, Mikropoulos HE. Cluster headaches. *Neurology (Minneapolis)*. 1958;8:653-663.
354. Ekbom K. Patterns of cluster headache with a note on the relations to angina pectoris and peptic ulcer. *Acta Neurol Scand*. 1970;46:225-237.
355. Sutherland JM, Eadie MJ. Cluster headache. *Res Clin Stud Headache*. 1972;3:92-155.
356. Manzoni GC, Taga A, Russo M, Torelli P. Age of onset of episodic and chronic cluster headache - a review of a large case series from a single headache centre. *The Journal of Headache and Pain*. 2016;17(44).
357. Lance JW, Anthony M. Migrainous neuralgia or cluster headache? *Journal of the Neurological Sciences*. 1971;13:401-414.
358. Sjaastad O, Saunte C, Fredriksen TA. Bilaterality of cluster headache. *Cephalalgia*. 1985;5:55-58.
359. Young WB, Rozen TD. Bilateral cluster headache - case report and theory of (failed) contralateral suppression. *Cephalalgia*. 1999;19:188-190.
360. Donnet A, Lanteri-Minet M, Guegan-Massardier E, et al. Chronic cluster headache: a French clinical descriptive study. *J Neurol Neurosurg Psychiatry*. 2007;78(12):1354-1358.
361. Hornabrook RW. Migrainous neuralgia. *New Zealand Medical Journal*. 1964;63:774-779.
362. Kudrow L. The cyclic relationship of natural illumination to cluster period frequency. *Cephalalgia*. 1987;7(6):76-78.
363. Russell D. Cluster headache: severity and temporal profiles of attacks and patient activity prior to and during attacks. *Cephalalgia*. 1981;1:209-216.
364. Barloese MC, P.J. J, Lund NT, Jensen RH. Sleep in cluster headache - beyond a temporal rapid eye movement relationship? *European Journal of Neurology*. 2015;22(4):656-e640.
365. Marmura MJ, Pello S, Fau - Young WB, Young WB. Interictal pain in cluster headache. *Cephalalgia*. 2010;30(12):1531-1534.
366. Ekbom K. Nitroglycerin as a provocative agent in cluster headache. *Arch Neurol*. 1968;19:487-493.
367. Rozen TD, Fishman RS. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. *Headache*. 2012;52(1):99-113.
368. Ekbom K, Group TSCHS. Treatment of acute cluster headache with sumatriptan. *The New England Journal of Medicine*. 1991;325(5):322-326.
369. Ekbom K, Cole JA. Subcutaneous sumatriptan in the acute treatment of cluster headache attacks. *Canadian Journal of Neurological Science*. 1993;20(supplement 4):61.
370. Ekbom K, Krabbe A, Fau - Micieli G, Micieli G, Fau - Prusinski A, et al. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-term Study Group. *Cephalalgia*. 1995;15(5):446.
371. Gobel H, Lindner A, Ribbat M, Deuschl G. Acute therapy for cluster headache with sumatriptan: Findings of a one-year long-term study. *Neurology*. 1998;51:908-911.
372. Hering-Hanit R. Alteration in nature of cluster headache during subcutaneous administration of sumatriptan. *Headache*. 2000;40(1):41-44.
373. Fogan L. Treatment of cluster headache. *Archives of Neurology*. 1985;42(4):362-363.
374. Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: a randomized trial. *JAMA*. 2009;302(22):2451-2457.
375. Law S, Derry S, Fau - Moore RA, Moore RA. Triptans for acute cluster headache. *Cochrane Database Syst Rev*. 2010;4(1469-493X (Electronic)):CD008042.
376. Cittadini E, May A, Straube A, Evers S, Bussone G, Goadsby PJ. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomised placebo-controlled crossover study. *Archives of Neurology*. 2006;63(11):1537-1542.
377. Rapoport AM, Mathew N, Fau - Silberstein SD, Silberstein S, Fau - Dodick D, et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. *Neurology*. 2007;69(9):821-826.
378. Hedlund C, Rapoport A, Fau - Dodick DW, Dodick D, Fau - Goadsby PJ, Goadsby PJ. Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies. *Headache*. 2009;49(9):1315-1323.
379. Goadsby PJ, de Coo IF, Silver N, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. *Cephalalgia*. 2018;38(5):959-969.
380. Robbins L. Intranasal lidocaine for cluster headache. *Headache*. 1995;35:83-84.
381. Matharu MS, Levy M, Meeran K, Goadsby PJ. Subcutaneous octreotide in cluster headache: Randomised placebo-controlled double-blind crossover study. *Annals of Neurology*. 2004;56:488-494.
382. Barloese MC, Jurgens TP, May A, et al. Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months. *Headache*. 2016;56(1):67-74.
383. Goadsby PJ, Sahai-Srivastava S, Kezirian EJ, Calhoun AH, Matthews DC, PJ M. Sphenopalatine Ganglion Stimulation is Effective for Chronic Cluster Headache - A Sham-Controlled Study (Abstract). 60th Annual Scientific Meeting American Headache Society@ June 28-July 1, 2018 Marquis San Francisco San Francisco, CA. *Headache: The Journal of Head and Face Pain*. 2018;58(8):1316-1317.
384. Leone M, D'Amico D, Frediani F, et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. *Neurology*. 2000;54(6):1382-1385.
385. Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. *Neurology*. 2007;69(7):668-675.
386. Lanteri-Minet M, Silhol F, Fau - Piano V, Piano V, Fau - Donnet A, Donnet A. Cardiac safety in cluster headache patients using the very high dose of verapamil (≥ 720 mg/day). *Journal of Headache and Pain*. 2011;12(2):173-176.
387. Jammes JL. The treatment of cluster headaches with prednisone. *Diseases of the Nervous System*. 1975;36(7):375-376.
388. Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: A

- double-blind placebo-controlled study. *Pain*. 2005;118:92-96.
389. Leroux E, Valade D Fau - Taifas I, Taifas I Fau - Vicaut E, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. *Lancet Neurology*. 2011;10(891-897).
390. Bussone G, Leone M, Peccarisi C, et al. Double-blind comparison of lithium and verapamil in cluster headache prophylaxis. *Headache*. 1990;30(7):411-417.
391. Leone M, D DA, Moschiano F, Fraschini F, Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. *Cephalalgia*. 1996;16(7):494-496.
392. Couch JR, Ziegler DK. Prednisone therapy for cluster headache. *Headache*. 1978;18:219-221.
393. Schoenen J, Jensen RH, Lanteri-Minet M, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. *Cephalalgia*. 2013;33(10):816-830.
394. Sjaastad O, Bakkeiteig LS. The rare, unilateral headaches. Vaga study of headache epidemiology. *Journal of Headache and Pain*. 2007;8(1):19-27.
395. Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: a prospective clinical study of thirty-one cases. *Brain*. 2008;131(Pt 4):1142-1155.
396. Prakash S, Belani P, Susvirkar A, Trivedi A, Ahuja S, Patel A. Paroxysmal hemicrania: a retrospective study of a consecutive series of 22 patients and a critical analysis of the diagnostic criteria. *The Journal of Headache and Pain*. 2013;14:1-8.
397. Antonaci F, Sjaastad O. Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. *Headache*. 1989;29(10):648-656.
398. Dahlof C. Subcutaneous sumatriptan does not abort attacks of chronic paroxysmal hemicrania (CPH). *Headache*. 1993;33:201-202.
399. Antonaci F, Pareja J, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: lack of efficacy of sumatriptan. *Headache*. 1998;38(3):197-200.
400. Pareja JA, Caminero A, Franco E, Casado JL, Pascual J, Sanchez del Rio M. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. *Cephalalgia*. 2001;21(9):906-910.
401. Williams MH, Broadley SA. SUNCT and SUNA: clinical features and medical treatment. *J Clin Neurosci*. 2008;15(5):526-534.
402. Sjaastad O, Bakkeiteig LS. Cluster headache prevalence. Vågå study of headache epidemiology. *Cephalalgia*. 2003;23(7):528-533.
403. Favoni V, Grimaldi D, Pierangeli G, Cortelli P, Cevoli S. SUNCT/SUNA and neurovascular compression: new cases and critical literature review. *Cephalalgia*. 2013;33(16):1337-1348.
404. Pareja JA, Kruszewski P, Sjaastad O. SUNCT syndrome: trials of drugs and anaesthetic blockades. *Headache*. 1995;35(3):138-142.
405. Cosentino G, Fierro B Fau - Puma AR, Puma AR Fau - Talamanca S, Talamanca S Fau - Brighina F, Brighina F. Different forms of trigeminal autonomic cephalalgias in the same patient: description of a case. *Journal of Headache and Pain*. 2010;11(3):281-284.
406. Robbins MS, Grosberg Bm Fau - Lipton RB, Lipton RB. Coexisting trigeminal autonomic cephalalgias and hemicrania continua. *Headache*. 2010;50(3):489-496.
407. Totzeck A, Diener Hc Fau - Gaul C, Gaul C. Concomitant occurrence of different trigeminal autonomic cephalalgias: a case series and review of the literature. *Cephalalgia*. 2014;34(3):231-235.
408. Bigal ME, Lipton Rb Fau - Tepper SJ, Tepper Sj Fau - Rapoport AM, Rapoport Am Fau - Sheftell FD, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. *Neurology*. 2004;63(5):643-647.
409. Ramon C, Mauri G Fau - Vega J, Vega J Fau - Rico M, Rico M Fau - Para M, Para M Fau - Pascual J, Pascual J. Diagnostic distribution of 100 unilateral, side-locked headaches consulting a specialized clinic. *European Neurology*. 2013;69(5):289-291.
410. Peres MFP, Silberstein SD, Nahmias S, et al. Hemicrania continua is not that rare. *Neurology*. 2001;57:948-951.
411. Cortijo E, Guerrero Al Fau - Herrero S, Herrero S Fau - Mulero P, et al. Hemicrania continua in a headache clinic: referral source and diagnostic delay in a series of 22 patients. *Journal of Headache and Pain*. 2012;13(7):567-569.
412. Matharu MS, Cohen As Fau - McGonigle DJ, McGonigle Dj Fau - Ward N, Ward N Fau - Frackowiak RS, Frackowiak Rs Fau - Goadsby PJ, Goadsby PJ. Posterior hypothalamic and brainstem activation in hemicrania continua. *Headache*. 2004;44(8):747-761.
413. Newman HC, Lipton RB, Solomon S. Hemicrania continua: ten new cases and a review of the literature. *Neurology*. 1994;44(11):2111-2114.
414. Prakash S, Golwala P. A proposal for revision of hemicrania continua diagnostic criteria based on critical analysis of 62 patients. *Cephalalgia*. 2012;32(11):860-868.
415. Joubert J. Hemicrania continua in a black patient-the importance of the non-continuous stage. *Headache*. 1991;31(7):480-482.
416. Pareja JA. Hemicrania continua: remitting stage evolved from the chronic form. *Headache*. 1995;35(3):161-162.
417. Peres MF, Stiles M, Oshinsky M, Rozen TD. Remitting form of hemicrania continua with seasonal pattern. *Headache*. 2001;41(6):592-594.
418. Kuhn J, Kuhn KF, Cooper-Mahkom D, Bewermeyer H. Remitting form of hemicrania continua: two new cases exhibiting one unusual autonomic feature. *Headache*. 2005;45(6):759-762.
419. Yablon LA, Newman LC. Hemicrania continua: a second case in which the remitting form evolved from the chronic form. *Headache*. 2010;50(8):1381-1383.
420. Terlizzi R, S. C, Nicodemo M, Pierangeli G, Grimaldi D, Cortelli P. A case of strictly unilateral migraine without aura transformed in an episodic hemicrania continua. *Neurological Sciences*. 2011;32(1):169-170.
421. Young WB, Silberstein SD. Hemicrania continua and symptomatic medication overuse. *Headache*. 1993;33(9):485-487.
422. Weatherall MW, Bahra A. Familial hemicrania continua. *Cephalalgia*. 2011;31(2):245-249.
423. Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. *Am J Med*. 2006;119(4 Suppl 1):S32-37.
424. Robbins JM, Thatcher GE, Webb DA, Valdmanis VG. Nutritionist visits, diabetes classes, and hospitalization rates and charges: the Urban Diabetes Study. *Diabetes Care*. 2008;31(4):655-660.

425. Allen W, Smith A. Effects of video podcasting on psychomotor and cognitive performance, attitudes and study behaviour of student physical therapists. In. Vol 49. *Innovations in Education and Teaching International*2012:401-414.
426. Hsin W, Cigas J. Short videos improve student learning in online education. In. Vol 28. *Journal of Computing Sciences in Colleges*2013:253-259.
427. Kay R. Exploring the use of video podcasts in education: A comprehensive review of the literature. In. Vol 28. *Computers in Human Behavior*2012:820-831.
428. Lloyd S, Robertson C. Screencast tutorials enhance student learning of statistics. In. Vol 39. *Teaching of Psychology*2012:67-71.
429. Rackaway C. Video killed the textbook star? Use of multimedia supplements to enhance student learning. In. Vol 8. *Journal of Political Science Education*2012:189-200.
430. Mayer R. Applying the science of learning: Evidence-based principles for the design of multimedia instruction. In. Vol 19. *Cognition and Instruction*2008:177-213.
431. Guo P, Kim J, Robin R. How video production affects student engagement: An empirical study of MOOC video. In. *ACM Conference on Learning at Scale (L@S 2014)*2014.
432. Shin HE, Park JW, Kim YI, Lee KS. Headache Impact Test-6 (HIT-6) scores for migraine patients: Their relation to disability as measured from a headache diary. *J Clin Neurol.* 2008;4(4):158-163.